Viewing Study NCT03781167

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 12:56 AM

Ignite Modification Date: 2026-02-25 @ 7:02 PM

Study NCT ID: NCT03781167

Status: COMPLETED

Last Update Posted: 2023-10-23

First Post: 2018-12-18

Is NOT Gene Therapy: True

Has Adverse Events: True

Brief Title: A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Sponsor:

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Raw JSON

{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['France'], 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2023-09-08', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D010300', 'term': 'Parkinson Disease'}], 'ancestors': [{'id': 'D020734', 'term': 'Parkinsonian Disorders'}, {'id': 'D001480', 'term': 'Basal Ganglia Diseases'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D009069', 'term': 'Movement Disorders'}, {'id': 'D000080874', 'term': 'Synucleinopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'abbvieclinicaltrials@abbvie.com', 'phone': '800-633-9110', 'title': 'Global Medical Services', 'organization': 'AbbVie'}, 'certainAgreement': {'otherDetails': 'AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'All-cause mortality is reported from enrollment to end of study; median time on follow-up was 367.0 days for the ABBV-951 Low Dose Subgroup, the ABBV-951 High Dose Subgroup, and the ABBV-951 All Participants group. TEAEs and SAEs were collected from first dose of study drug until 30 days after the last infusion; mean time on treatment was 244.9 days for the ABBV-951 Low Dose Subgroup, 240.6 days for the ABBV-951 High Dose Subgroup, and 242.9 days for the ABBV-951 All Participants group.', 'eventGroups': [{'id': 'EG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.', 'otherNumAtRisk': 131, 'deathsNumAtRisk': 131, 'otherNumAffected': 111, 'seriousNumAtRisk': 131, 'deathsNumAffected': 0, 'seriousNumAffected': 32}, {'id': 'EG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.', 'otherNumAtRisk': 113, 'deathsNumAtRisk': 113, 'otherNumAffected': 107, 'seriousNumAtRisk': 113, 'deathsNumAffected': 5, 'seriousNumAffected': 31}, {'id': 'EG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.', 'otherNumAtRisk': 244, 'deathsNumAtRisk': 244, 'otherNumAffected': 218, 'seriousNumAtRisk': 244, 'deathsNumAffected': 5, 'seriousNumAffected': 63}], 'otherEvents': [{'term': 'CONSTIPATION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 8, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 12, 'numAffected': 12}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 20, 'numAffected': 20}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'NAUSEA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 11, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 13, 'numAffected': 11}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 24, 'numAffected': 19}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE BRUISING', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 15, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 15, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 30, 'numAffected': 18}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE ERYTHEMA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 175, 'numAffected': 64}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 168, 'numAffected': 63}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 343, 'numAffected': 127}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE EXTRAVASATION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 10, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 15, 'numAffected': 12}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 25, 'numAffected': 20}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE HAEMATOMA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 10, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 12, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 22, 'numAffected': 17}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE INFLAMMATION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 9, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 12, 'numAffected': 9}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE NODULE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 65, 'numAffected': 36}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 58, 'numAffected': 34}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 123, 'numAffected': 70}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE OEDEMA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 78, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 45, 'numAffected': 28}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 123, 'numAffected': 47}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE PAIN', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 41, 'numAffected': 18}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 27, 'numAffected': 20}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 68, 'numAffected': 38}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE PAPULE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 18, 'numAffected': 11}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 26, 'numAffected': 18}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE REACTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 26, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 36, 'numAffected': 17}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 62, 'numAffected': 30}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INJECTION SITE ERYTHEMA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 22, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 14, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 36, 'numAffected': 14}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INJECTION SITE NODULE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 15, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 8, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 23, 'numAffected': 9}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INJECTION SITE PAIN', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 8, 'numAffected': 8}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE ABSCESS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 9, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 12, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 21, 'numAffected': 19}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE CELLULITIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 33, 'numAffected': 25}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 31, 'numAffected': 21}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 64, 'numAffected': 46}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE INFECTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 16, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 24, 'numAffected': 17}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'URINARY TRACT INFECTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 14, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 21, 'numAffected': 15}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'CONTUSION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 9, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 12, 'numAffected': 8}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'FALL', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 42, 'numAffected': 16}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 35, 'numAffected': 23}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 77, 'numAffected': 39}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'SKIN LACERATION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'VITAMIN B6 DECREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 11, 'numAffected': 11}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'WEIGHT DECREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 10, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 14, 'numAffected': 14}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 24, 'numAffected': 24}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'BACK PAIN', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 8, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 6, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 14, 'numAffected': 13}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'DIZZINESS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 18, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 10, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 28, 'numAffected': 24}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'DYSKINESIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 20, 'numAffected': 12}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 27, 'numAffected': 18}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'HEADACHE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 10, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 17, 'numAffected': 14}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': "PARKINSON'S DISEASE", 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 12, 'numAffected': 11}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'SOMNOLENCE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 11, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 14, 'numAffected': 12}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'ANXIETY', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 12, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 22, 'numAffected': 18}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 34, 'numAffected': 28}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'DELUSION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 8, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 9, 'numAffected': 8}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'HALLUCINATION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 22, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 27, 'numAffected': 21}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 49, 'numAffected': 35}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'HALLUCINATION, VISUAL', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 14, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 6, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 20, 'numAffected': 15}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INSOMNIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 9, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 9, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 18, 'numAffected': 18}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'ORTHOSTATIC HYPOTENSION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 13, 'numAffected': 12}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}], 'seriousEvents': [{'term': 'ACUTE MYOCARDIAL INFARCTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'ATRIAL FIBRILLATION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'CARDIAC ARREST', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'CARDIO-RESPIRATORY ARREST', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'CORONARY ARTERY DISEASE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'PERIORBITAL PAIN', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'PERIORBITAL SWELLING', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'COLITIS ISCHAEMIC', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INTESTINAL HAEMORRHAGE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'ASTHENIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'CHEST DISCOMFORT', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'CHEST PAIN', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'HYPOTHERMIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE HAEMATOMA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE INJURY', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'ABSCESS LIMB', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'COVID-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'CELLULITIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE ABSCESS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 10, 'numAffected': 8}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE CELLULITIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 10, 'numAffected': 10}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'INFUSION SITE INFECTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'PAROTID ABSCESS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'PNEUMONIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 4, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'SEPSIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'SEPTIC SHOCK', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'URINARY TRACT INFECTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'FACE INJURY', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'FALL', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'SUBDURAL HAEMATOMA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'BLOOD SODIUM DECREASED', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'DEHYDRATION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'HYPOKALAEMIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'HYPONATRAEMIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'ARTHRITIS REACTIVE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'OSTEOARTHRITIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'RHABDOMYOLYSIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'SACROILIAC JOINT DYSFUNCTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'RECTAL ADENOCARCINOMA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'CEREBRAL MASS EFFECT', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'CEREBROVASCULAR ACCIDENT', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'COGNITIVE DISORDER', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'DIZZINESS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'DYSARTHRIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'DYSTONIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 3, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'GENERALISED TONIC-CLONIC SEIZURE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'HEMIANAESTHESIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'HEMIPARESIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'LOSS OF CONSCIOUSNESS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'LUMBOSACRAL RADICULOPATHY', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'ON AND OFF PHENOMENON', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'PARAESTHESIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': "PARKINSON'S DISEASE", 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 6, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 7, 'numAffected': 6}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'PARKINSONISM', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'PSYCHOGENIC SEIZURE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'ANXIETY', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'CONFUSIONAL STATE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'DELIRIUM', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'DELUSION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'DELUSIONAL DISORDER, UNSPECIFIED TYPE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'DOPAMINE DYSREGULATION SYNDROME', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'HALLUCINATION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'PSYCHOTIC DISORDER', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 7, 'numAffected': 6}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'SUICIDE ATTEMPT', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'BRONCHIECTASIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'DYSPNOEA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'HYPERVENTILATION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'PULMONARY EMBOLISM', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'HAEMATOMA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'HAEMORRHAGE', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}, {'term': 'ORTHOSTATIC HYPOTENSION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 131, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 113, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 244, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 24.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Participants With Adverse Events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Any TEAE', 'categories': [{'measurements': [{'value': '121', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '230', 'groupId': 'OG002'}]}]}, {'title': 'TESAE', 'categories': [{'measurements': [{'value': '32', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From first dose of study drug until 30 days following last dose of study drug (up to 480 days)', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.', 'calculatePct': False, 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Adverse Events of Special Interest', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Infusion site infections', 'categories': [{'measurements': [{'value': '42', 'groupId': 'OG000'}, {'value': '44', 'groupId': 'OG001'}, {'value': '86', 'groupId': 'OG002'}]}]}, {'title': 'Infusion site reactions', 'categories': [{'measurements': [{'value': '103', 'groupId': 'OG000'}, {'value': '97', 'groupId': 'OG001'}, {'value': '200', 'groupId': 'OG002'}]}]}, {'title': 'Hallucinations/psychosis', 'categories': [{'measurements': [{'value': '32', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}, {'value': '61', 'groupId': 'OG002'}]}]}, {'title': 'Falls and associated injuries', 'categories': [{'measurements': [{'value': '37', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '74', 'groupId': 'OG002'}]}]}, {'title': 'Polyneuropathy (peripheral neuropathy)', 'categories': [{'measurements': [{'value': '14', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}]}]}, {'title': 'Weight loss', 'categories': [{'measurements': [{'value': '12', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}]}]}, {'title': 'Somnolence', 'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From first dose of study drug until 30 days following last dose of study drug (up to 480 days)', 'description': 'Treatment emergent adverse events of special interest are defined as any adverse event of infusion site infections, infusion site reactions, hallucinations/psychosis, falls and associated injuries, polyneuropathy (peripheral neuropathy), weight loss, or somnolence from the first dose of study drug until 30 days following last dose of study drug.', 'calculatePct': False, 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Numeric Grade Equal to or Higher Than 5 and With Letter Grade Equal to or Higher Than D on the Infusion Site Evaluation Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'categories': [{'measurements': [{'value': '10', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '25', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1, Day 2, Week 1, Week 2, Week 3, Week 4, Week 6, Week 13, Week 26, Week 39, and Week 52', 'description': 'Skin tolerability was assessed using the Infusion Site Evaluation Scale, a 2-part numeric (0-7) and letter (A-G) grade scale, where a notable skin reaction is defined as a reaction with a numeric grade of 6 or 7 or a letter grade of D, E, F, or G. Any observation of infusion site reaction with irritation criteria \\> 2 or \\> C was recorded as an adverse event (AE).', 'calculatePct': False, 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion'}, {'type': 'PRIMARY', 'title': 'Hematocrit (Hematology): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '128', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '241', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '94', 'groupId': 'OG000'}, {'value': '91', 'groupId': 'OG001'}, {'value': '185', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.031', 'groupId': 'OG000'}, {'value': '-0.02', 'spread': '0.029', 'groupId': 'OG001'}, {'value': '-0.02', 'spread': '0.030', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.01', 'spread': '0.030', 'groupId': 'OG000'}, {'value': '-0.02', 'spread': '0.026', 'groupId': 'OG001'}, {'value': '-0.02', 'spread': '0.028', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '114', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.028', 'groupId': 'OG000'}, {'value': '-0.02', 'spread': '0.029', 'groupId': 'OG001'}, {'value': '-0.02', 'spread': '0.028', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '62', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '118', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.029', 'groupId': 'OG000'}, {'value': '-0.02', 'spread': '0.028', 'groupId': 'OG001'}, {'value': '-0.02', 'spread': '0.029', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'proportion of red blood cells in blood', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Hemoglobin (Hematology): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '243', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '98', 'groupId': 'OG000'}, {'value': '93', 'groupId': 'OG001'}, {'value': '191', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-5.00', 'spread': '8.308', 'groupId': 'OG000'}, {'value': '-6.82', 'spread': '9.222', 'groupId': 'OG001'}, {'value': '-5.89', 'spread': '8.789', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '134', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-5.42', 'spread': '9.296', 'groupId': 'OG000'}, {'value': '-4.48', 'spread': '7.502', 'groupId': 'OG001'}, {'value': '-4.98', 'spread': '8.482', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '121', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-5.74', 'spread': '8.430', 'groupId': 'OG000'}, {'value': '-6.58', 'spread': '8.601', 'groupId': 'OG001'}, {'value': '-6.11', 'spread': '8.480', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-7.96', 'spread': '8.862', 'groupId': 'OG000'}, {'value': '-5.80', 'spread': '9.308', 'groupId': 'OG001'}, {'value': '-6.99', 'spread': '9.091', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'g/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Red Blood Cell (RBC) Count (Hematology): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '243', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '96', 'groupId': 'OG000'}, {'value': '93', 'groupId': 'OG001'}, {'value': '189', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.15', 'spread': '0.261', 'groupId': 'OG000'}, {'value': '-0.21', 'spread': '0.296', 'groupId': 'OG001'}, {'value': '-0.18', 'spread': '0.280', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '134', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.12', 'spread': '0.295', 'groupId': 'OG000'}, {'value': '-0.13', 'spread': '0.273', 'groupId': 'OG001'}, {'value': '-0.13', 'spread': '0.284', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '121', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.14', 'spread': '0.271', 'groupId': 'OG000'}, {'value': '-0.19', 'spread': '0.290', 'groupId': 'OG001'}, {'value': '-0.17', 'spread': '0.279', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.21', 'spread': '0.291', 'groupId': 'OG000'}, {'value': '-0.16', 'spread': '0.293', 'groupId': 'OG001'}, {'value': '-0.19', 'spread': '0.292', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'cells*10^12/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'White Blood Cell (WBC) Count (Hematology): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '243', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '98', 'groupId': 'OG000'}, {'value': '93', 'groupId': 'OG001'}, {'value': '191', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '1.705', 'groupId': 'OG000'}, {'value': '0.32', 'spread': '2.120', 'groupId': 'OG001'}, {'value': '0.17', 'spread': '1.919', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '134', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.12', 'spread': '1.892', 'groupId': 'OG000'}, {'value': '0.22', 'spread': '2.990', 'groupId': 'OG001'}, {'value': '0.17', 'spread': '2.460', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '122', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.35', 'spread': '4.014', 'groupId': 'OG000'}, {'value': '0.38', 'spread': '1.670', 'groupId': 'OG001'}, {'value': '0.36', 'spread': '3.202', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.08', 'spread': '2.027', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '1.568', 'groupId': 'OG001'}, {'value': '-0.06', 'spread': '1.829', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'cells*10^9/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Neutrophils (Hematology): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '243', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '97', 'groupId': 'OG000'}, {'value': '92', 'groupId': 'OG001'}, {'value': '189', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '1.720', 'groupId': 'OG000'}, {'value': '0.33', 'spread': '2.102', 'groupId': 'OG001'}, {'value': '0.17', 'spread': '1.917', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '134', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '1.813', 'groupId': 'OG000'}, {'value': '143.08', 'spread': '1133.988', 'groupId': 'OG001'}, {'value': '67.25', 'spread': '777.558', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '121', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.23', 'spread': '2.380', 'groupId': 'OG000'}, {'value': '0.18', 'spread': '1.635', 'groupId': 'OG001'}, {'value': '-0.05', 'spread': '2.089', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.14', 'spread': '1.986', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '1.498', 'groupId': 'OG001'}, {'value': '-0.10', 'spread': '1.778', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'cells*10^9/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Lymphocytes (Hematology): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '243', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '97', 'groupId': 'OG000'}, {'value': '92', 'groupId': 'OG001'}, {'value': '189', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.06', 'spread': '0.305', 'groupId': 'OG000'}, {'value': '-0.07', 'spread': '0.326', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.321', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '134', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.09', 'spread': '0.331', 'groupId': 'OG000'}, {'value': '13.92', 'spread': '110.588', 'groupId': 'OG001'}, {'value': '6.59', 'spread': '75.823', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '121', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.394', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '0.312', 'groupId': 'OG001'}, {'value': '0.03', 'spread': '0.359', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.04', 'spread': '0.394', 'groupId': 'OG000'}, {'value': '-0.05', 'spread': '0.294', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.354', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'cells*10^9/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Monocytes (Hematology): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '243', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '96', 'groupId': 'OG000'}, {'value': '92', 'groupId': 'OG001'}, {'value': '188', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.127', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '0.123', 'groupId': 'OG001'}, {'value': '0.01', 'spread': '0.125', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '134', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.095', 'groupId': 'OG000'}, {'value': '17.43', 'spread': '138.498', 'groupId': 'OG001'}, {'value': '8.21', 'spread': '94.963', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '121', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.120', 'groupId': 'OG000'}, {'value': '0.03', 'spread': '0.122', 'groupId': 'OG001'}, {'value': '0.02', 'spread': '0.120', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.109', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '0.132', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.119', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'cells*10^9/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Absolute Platelet Count (Hematology): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '112', 'groupId': 'OG001'}, {'value': '242', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '96', 'groupId': 'OG000'}, {'value': '92', 'groupId': 'OG001'}, {'value': '188', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.59', 'spread': '36.489', 'groupId': 'OG000'}, {'value': '0.39', 'spread': '40.844', 'groupId': 'OG001'}, {'value': '2.54', 'spread': '38.635', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '133', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.68', 'spread': '43.279', 'groupId': 'OG000'}, {'value': '-10.39', 'spread': '43.757', 'groupId': 'OG001'}, {'value': '-5.74', 'spread': '43.556', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '52', 'groupId': 'OG001'}, {'value': '120', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.90', 'spread': '43.848', 'groupId': 'OG000'}, {'value': '-7.29', 'spread': '49.222', 'groupId': 'OG001'}, {'value': '-5.37', 'spread': '46.084', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '123', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.41', 'spread': '41.120', 'groupId': 'OG000'}, {'value': '-10.63', 'spread': '44.537', 'groupId': 'OG001'}, {'value': '-6.58', 'spread': '42.628', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'cells*10^9/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Mean Corpuscular Hemoglobin (Hematology): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '243', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '96', 'groupId': 'OG000'}, {'value': '92', 'groupId': 'OG001'}, {'value': '188', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.09', 'spread': '0.822', 'groupId': 'OG000'}, {'value': '-0.15', 'spread': '0.825', 'groupId': 'OG001'}, {'value': '-0.12', 'spread': '0.821', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '133', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.38', 'spread': '1.033', 'groupId': 'OG000'}, {'value': '0.05', 'spread': '1.078', 'groupId': 'OG001'}, {'value': '-0.18', 'spread': '1.072', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '121', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.34', 'spread': '1.205', 'groupId': 'OG000'}, {'value': '-0.08', 'spread': '0.978', 'groupId': 'OG001'}, {'value': '-0.22', 'spread': '1.114', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.36', 'spread': '1.124', 'groupId': 'OG000'}, {'value': '-0.07', 'spread': '1.142', 'groupId': 'OG001'}, {'value': '-0.23', 'spread': '1.137', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'picograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Mean Corpuscular Volume Concentration (MCHC) (Hematology): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '128', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '241', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '93', 'groupId': 'OG000'}, {'value': '90', 'groupId': 'OG001'}, {'value': '183', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.15', 'spread': '11.689', 'groupId': 'OG000'}, {'value': '1.78', 'spread': '10.870', 'groupId': 'OG001'}, {'value': '1.97', 'spread': '11.264', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '60', 'groupId': 'OG001'}, {'value': '129', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.30', 'spread': '14.844', 'groupId': 'OG000'}, {'value': '2.17', 'spread': '15.741', 'groupId': 'OG001'}, {'value': '0.31', 'spread': '15.306', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '114', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.13', 'spread': '13.677', 'groupId': 'OG000'}, {'value': '-2.64', 'spread': '14.826', 'groupId': 'OG001'}, {'value': '-2.37', 'spread': '14.161', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '62', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '118', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.16', 'spread': '12.609', 'groupId': 'OG000'}, {'value': '0.18', 'spread': '13.684', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '13.074', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'g/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Prothrombin Time (PT) (Hematology): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '93', 'groupId': 'OG001'}, {'value': '193', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.480', 'groupId': 'OG000'}, {'value': '-0.09', 'spread': '2.556', 'groupId': 'OG001'}, {'value': '-0.03', 'spread': '1.803', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '57', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.08', 'spread': '1.026', 'groupId': 'OG000'}, {'value': '-0.36', 'spread': '3.187', 'groupId': 'OG001'}, {'value': '-0.20', 'spread': '2.261', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '121', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.10', 'spread': '0.569', 'groupId': 'OG000'}, {'value': '-0.21', 'spread': '3.396', 'groupId': 'OG001'}, {'value': '-0.03', 'spread': '2.239', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '52', 'groupId': 'OG001'}, {'value': '124', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.10', 'spread': '0.889', 'groupId': 'OG000'}, {'value': '-0.22', 'spread': '3.703', 'groupId': 'OG001'}, {'value': '-0.04', 'spread': '2.483', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'seconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Activated Partial Thromboplastin Time (Hematology): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '93', 'groupId': 'OG001'}, {'value': '193', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.27', 'spread': '2.151', 'groupId': 'OG000'}, {'value': '0.55', 'spread': '2.483', 'groupId': 'OG001'}, {'value': '0.13', 'spread': '2.347', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '57', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '1.898', 'groupId': 'OG000'}, {'value': '0.48', 'spread': '1.932', 'groupId': 'OG001'}, {'value': '0.20', 'spread': '1.922', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '121', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.14', 'spread': '1.556', 'groupId': 'OG000'}, {'value': '0.67', 'spread': '3.672', 'groupId': 'OG001'}, {'value': '0.36', 'spread': '2.661', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '122', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.09', 'spread': '2.156', 'groupId': 'OG000'}, {'value': '0.88', 'spread': '2.992', 'groupId': 'OG001'}, {'value': '0.32', 'spread': '2.573', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'seconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Blood Urea Nitrogen (BUN) (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '199', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '1.348', 'groupId': 'OG000'}, {'value': '-0.01', 'spread': '1.560', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '1.450', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '137', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.21', 'spread': '1.489', 'groupId': 'OG000'}, {'value': '0.17', 'spread': '1.600', 'groupId': 'OG001'}, {'value': '0.19', 'spread': '1.535', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.41', 'spread': '1.852', 'groupId': 'OG000'}, {'value': '0.05', 'spread': '1.659', 'groupId': 'OG001'}, {'value': '0.25', 'spread': '1.773', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.16', 'spread': '1.836', 'groupId': 'OG000'}, {'value': '0.15', 'spread': '1.342', 'groupId': 'OG001'}, {'value': '0.16', 'spread': '1.636', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Creatinine (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '104', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '200', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-4.45', 'spread': '9.227', 'groupId': 'OG000'}, {'value': '-5.67', 'spread': '10.725', 'groupId': 'OG001'}, {'value': '-5.04', 'spread': '9.968', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '138', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.71', 'spread': '10.478', 'groupId': 'OG000'}, {'value': '-4.07', 'spread': '12.074', 'groupId': 'OG001'}, {'value': '-3.33', 'spread': '11.213', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.47', 'spread': '12.414', 'groupId': 'OG000'}, {'value': '-4.02', 'spread': '10.182', 'groupId': 'OG001'}, {'value': '-2.58', 'spread': '11.527', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-4.78', 'spread': '11.446', 'groupId': 'OG000'}, {'value': '-5.21', 'spread': '9.941', 'groupId': 'OG001'}, {'value': '-4.96', 'spread': '10.785', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'µmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Creatine Phosphokinase (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '199', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.52', 'spread': '56.209', 'groupId': 'OG000'}, {'value': '-11.01', 'spread': '94.662', 'groupId': 'OG001'}, {'value': '-4.01', 'spread': '77.285', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '136', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '5.61', 'spread': '51.627', 'groupId': 'OG000'}, {'value': '-15.44', 'spread': '62.435', 'groupId': 'OG001'}, {'value': '-3.83', 'spread': '57.480', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '126', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '8.40', 'spread': '96.021', 'groupId': 'OG000'}, {'value': '-9.67', 'spread': '75.655', 'groupId': 'OG001'}, {'value': '0.66', 'spread': '88.002', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '30.39', 'spread': '125.044', 'groupId': 'OG000'}, {'value': '-16.55', 'spread': '85.305', 'groupId': 'OG001'}, {'value': '10.17', 'spread': '111.783', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Total Bilirubin (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '199', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.85', 'spread': '3.420', 'groupId': 'OG000'}, {'value': '-0.15', 'spread': '3.167', 'groupId': 'OG001'}, {'value': '-0.51', 'spread': '3.311', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '136', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.43', 'spread': '3.535', 'groupId': 'OG000'}, {'value': '0.28', 'spread': '2.814', 'groupId': 'OG001'}, {'value': '-0.11', 'spread': '3.240', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.71', 'spread': '2.881', 'groupId': 'OG000'}, {'value': '0.31', 'spread': '3.754', 'groupId': 'OG001'}, {'value': '-0.27', 'spread': '3.313', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.30', 'spread': '3.673', 'groupId': 'OG000'}, {'value': '-0.15', 'spread': '3.250', 'groupId': 'OG001'}, {'value': '-0.24', 'spread': '3.485', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'µmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Serum Alanine Aminotransferase (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '199', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-8.94', 'spread': '8.928', 'groupId': 'OG000'}, {'value': '-11.28', 'spread': '10.053', 'groupId': 'OG001'}, {'value': '-10.07', 'spread': '9.535', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '136', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-8.95', 'spread': '9.869', 'groupId': 'OG000'}, {'value': '-11.66', 'spread': '11.294', 'groupId': 'OG001'}, {'value': '-10.16', 'spread': '10.579', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-9.70', 'spread': '9.145', 'groupId': 'OG000'}, {'value': '-10.09', 'spread': '13.476', 'groupId': 'OG001'}, {'value': '-9.87', 'spread': '11.175', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '129', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-9.37', 'spread': '10.347', 'groupId': 'OG000'}, {'value': '-12.11', 'spread': '9.947', 'groupId': 'OG001'}, {'value': '-10.56', 'spread': '10.227', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Serum Aspartate Aminotransferase (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '102', 'groupId': 'OG000'}, {'value': '95', 'groupId': 'OG001'}, {'value': '197', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.89', 'spread': '4.881', 'groupId': 'OG000'}, {'value': '-2.21', 'spread': '6.163', 'groupId': 'OG001'}, {'value': '-2.05', 'spread': '5.524', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '59', 'groupId': 'OG001'}, {'value': '133', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.69', 'spread': '8.569', 'groupId': 'OG000'}, {'value': '-2.56', 'spread': '7.013', 'groupId': 'OG001'}, {'value': '-1.52', 'spread': '7.943', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '126', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.38', 'spread': '6.714', 'groupId': 'OG000'}, {'value': '-1.17', 'spread': '7.036', 'groupId': 'OG001'}, {'value': '-1.29', 'spread': '6.827', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '128', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.81', 'spread': '6.576', 'groupId': 'OG000'}, {'value': '-0.82', 'spread': '7.794', 'groupId': 'OG001'}, {'value': '-0.81', 'spread': '7.095', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Serum Lactate Dehydrogenase (LDH) (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '129', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '238', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '93', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '182', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-6.57', 'spread': '26.734', 'groupId': 'OG000'}, {'value': '-8.58', 'spread': '23.626', 'groupId': 'OG001'}, {'value': '-7.55', 'spread': '25.213', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '67', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '123', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.66', 'spread': '23.894', 'groupId': 'OG000'}, {'value': '-4.91', 'spread': '23.613', 'groupId': 'OG001'}, {'value': '-3.14', 'spread': '23.725', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '59', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '106', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.17', 'spread': '25.010', 'groupId': 'OG000'}, {'value': '-2.02', 'spread': '26.431', 'groupId': 'OG001'}, {'value': '-2.10', 'spread': '25.526', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '118', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.14', 'spread': '22.788', 'groupId': 'OG000'}, {'value': '3.32', 'spread': '26.413', 'groupId': 'OG001'}, {'value': '1.41', 'spread': '24.237', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Gamma-glutamyl Transferase (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '199', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.07', 'spread': '9.516', 'groupId': 'OG000'}, {'value': '-3.13', 'spread': '9.393', 'groupId': 'OG001'}, {'value': '-2.06', 'spread': '9.489', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '137', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.47', 'spread': '11.487', 'groupId': 'OG000'}, {'value': '-5.02', 'spread': '15.370', 'groupId': 'OG001'}, {'value': '-3.07', 'spread': '13.450', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '126', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.92', 'spread': '10.860', 'groupId': 'OG000'}, {'value': '-4.67', 'spread': '12.516', 'groupId': 'OG001'}, {'value': '-3.10', 'spread': '11.631', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.69', 'spread': '23.235', 'groupId': 'OG000'}, {'value': '-3.09', 'spread': '14.538', 'groupId': 'OG001'}, {'value': '-0.37', 'spread': '20.031', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Alkaline Phosphatase (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '199', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.91', 'spread': '12.394', 'groupId': 'OG000'}, {'value': '-4.56', 'spread': '12.340', 'groupId': 'OG001'}, {'value': '-3.19', 'spread': '12.408', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '138', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.68', 'spread': '18.995', 'groupId': 'OG000'}, {'value': '-2.86', 'spread': '14.157', 'groupId': 'OG001'}, {'value': '-0.39', 'spread': '17.051', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.28', 'spread': '12.252', 'groupId': 'OG000'}, {'value': '-5.02', 'spread': '16.088', 'groupId': 'OG001'}, {'value': '-3.46', 'spread': '14.049', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.55', 'spread': '18.637', 'groupId': 'OG000'}, {'value': '-1.54', 'spread': '13.796', 'groupId': 'OG001'}, {'value': '-0.35', 'spread': '16.697', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Sodium (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '95', 'groupId': 'OG001'}, {'value': '198', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.52', 'spread': '3.168', 'groupId': 'OG000'}, {'value': '-1.06', 'spread': '2.592', 'groupId': 'OG001'}, {'value': '-0.78', 'spread': '2.911', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '135', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.35', 'spread': '3.173', 'groupId': 'OG000'}, {'value': '-1.26', 'spread': '2.744', 'groupId': 'OG001'}, {'value': '-0.76', 'spread': '3.010', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.90', 'spread': '2.984', 'groupId': 'OG000'}, {'value': '-0.68', 'spread': '2.772', 'groupId': 'OG001'}, {'value': '-0.81', 'spread': '2.887', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '129', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.55', 'spread': '2.774', 'groupId': 'OG000'}, {'value': '-0.84', 'spread': '2.164', 'groupId': 'OG001'}, {'value': '-0.67', 'spread': '2.522', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Potassium (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '199', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.335', 'groupId': 'OG000'}, {'value': '-0.08', 'spread': '0.330', 'groupId': 'OG001'}, {'value': '-0.05', 'spread': '0.333', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '135', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.367', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.373', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.368', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '52', 'groupId': 'OG001'}, {'value': '124', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.01', 'spread': '0.389', 'groupId': 'OG000'}, {'value': '-0.09', 'spread': '0.382', 'groupId': 'OG001'}, {'value': '-0.04', 'spread': '0.387', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '129', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.10', 'spread': '0.369', 'groupId': 'OG000'}, {'value': '-0.03', 'spread': '0.338', 'groupId': 'OG001'}, {'value': '-0.07', 'spread': '0.357', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Calcium (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '199', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.079', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '0.086', 'groupId': 'OG001'}, {'value': '-0.03', 'spread': '0.083', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '138', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.080', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '0.091', 'groupId': 'OG001'}, {'value': '-0.03', 'spread': '0.085', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.091', 'groupId': 'OG000'}, {'value': '-0.05', 'spread': '0.087', 'groupId': 'OG001'}, {'value': '-0.05', 'spread': '0.089', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.06', 'spread': '0.084', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '0.092', 'groupId': 'OG001'}, {'value': '-0.05', 'spread': '0.088', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Inorganic Phosphorus (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '199', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.08', 'spread': '0.173', 'groupId': 'OG000'}, {'value': '0.08', 'spread': '0.168', 'groupId': 'OG001'}, {'value': '0.08', 'spread': '0.170', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '137', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.09', 'spread': '0.182', 'groupId': 'OG000'}, {'value': '0.09', 'spread': '0.170', 'groupId': 'OG001'}, {'value': '0.09', 'spread': '0.176', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.07', 'spread': '0.165', 'groupId': 'OG000'}, {'value': '0.08', 'spread': '0.155', 'groupId': 'OG001'}, {'value': '0.08', 'spread': '0.160', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.09', 'spread': '0.169', 'groupId': 'OG000'}, {'value': '0.08', 'spread': '0.172', 'groupId': 'OG001'}, {'value': '0.08', 'spread': '0.170', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Uric Acid (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '199', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-28.36', 'spread': '51.219', 'groupId': 'OG000'}, {'value': '-37.43', 'spread': '37.302', 'groupId': 'OG001'}, {'value': '-32.73', 'spread': '45.163', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '137', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-16.66', 'spread': '60.922', 'groupId': 'OG000'}, {'value': '-32.91', 'spread': '34.446', 'groupId': 'OG001'}, {'value': '-24.01', 'spread': '51.163', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-13.55', 'spread': '57.830', 'groupId': 'OG000'}, {'value': '-35.80', 'spread': '40.965', 'groupId': 'OG001'}, {'value': '-23.18', 'spread': '52.213', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-15.27', 'spread': '56.459', 'groupId': 'OG000'}, {'value': '-31.23', 'spread': '29.780', 'groupId': 'OG001'}, {'value': '-22.15', 'spread': '47.380', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'µmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Total Cholesterol (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '102', 'groupId': 'OG000'}, {'value': '95', 'groupId': 'OG001'}, {'value': '197', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.37', 'spread': '0.688', 'groupId': 'OG000'}, {'value': '-0.57', 'spread': '0.556', 'groupId': 'OG001'}, {'value': '-0.47', 'spread': '0.634', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '136', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.19', 'spread': '0.657', 'groupId': 'OG000'}, {'value': '-0.31', 'spread': '0.661', 'groupId': 'OG001'}, {'value': '-0.25', 'spread': '0.659', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.33', 'spread': '0.565', 'groupId': 'OG000'}, {'value': '-0.41', 'spread': '0.552', 'groupId': 'OG001'}, {'value': '-0.36', 'spread': '0.559', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '129', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.31', 'spread': '0.660', 'groupId': 'OG000'}, {'value': '-0.25', 'spread': '0.594', 'groupId': 'OG001'}, {'value': '-0.29', 'spread': '0.630', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Albumin (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '199', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.65', 'spread': '2.782', 'groupId': 'OG000'}, {'value': '-1.95', 'spread': '2.885', 'groupId': 'OG001'}, {'value': '-1.79', 'spread': '2.829', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '138', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.31', 'spread': '2.541', 'groupId': 'OG000'}, {'value': '-1.14', 'spread': '2.558', 'groupId': 'OG001'}, {'value': '-1.23', 'spread': '2.541', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.75', 'spread': '2.782', 'groupId': 'OG000'}, {'value': '-1.56', 'spread': '2.507', 'groupId': 'OG001'}, {'value': '-1.67', 'spread': '2.658', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.96', 'spread': '2.949', 'groupId': 'OG000'}, {'value': '-1.02', 'spread': '3.205', 'groupId': 'OG001'}, {'value': '-1.55', 'spread': '3.086', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'g/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Glucose (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '97', 'groupId': 'OG001'}, {'value': '200', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.39', 'spread': '1.186', 'groupId': 'OG000'}, {'value': '-0.39', 'spread': '1.438', 'groupId': 'OG001'}, {'value': '-0.39', 'spread': '1.311', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '138', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.37', 'spread': '1.271', 'groupId': 'OG000'}, {'value': '-0.14', 'spread': '1.486', 'groupId': 'OG001'}, {'value': '-0.27', 'spread': '1.373', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.33', 'spread': '1.181', 'groupId': 'OG000'}, {'value': '-0.60', 'spread': '1.327', 'groupId': 'OG001'}, {'value': '-0.45', 'spread': '1.249', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.32', 'spread': '1.917', 'groupId': 'OG000'}, {'value': '-0.55', 'spread': '1.479', 'groupId': 'OG001'}, {'value': '-0.42', 'spread': '1.740', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Sodium Bicarbonate/CO2 (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '243', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '94', 'groupId': 'OG001'}, {'value': '194', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.19', 'spread': '2.372', 'groupId': 'OG000'}, {'value': '0.97', 'spread': '2.518', 'groupId': 'OG001'}, {'value': '1.09', 'spread': '2.440', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '60', 'groupId': 'OG001'}, {'value': '131', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.77', 'spread': '2.418', 'groupId': 'OG000'}, {'value': '0.28', 'spread': '2.744', 'groupId': 'OG001'}, {'value': '0.55', 'spread': '2.574', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '67', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '117', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.90', 'spread': '2.240', 'groupId': 'OG000'}, {'value': '0.63', 'spread': '2.874', 'groupId': 'OG001'}, {'value': '0.78', 'spread': '2.522', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.78', 'spread': '2.374', 'groupId': 'OG000'}, {'value': '0.57', 'spread': '2.304', 'groupId': 'OG001'}, {'value': '0.69', 'spread': '2.337', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Magnesium (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '103', 'groupId': 'OG000'}, {'value': '95', 'groupId': 'OG001'}, {'value': '198', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.067', 'groupId': 'OG000'}, {'value': '-0.03', 'spread': '0.058', 'groupId': 'OG001'}, {'value': '-0.03', 'spread': '0.063', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '135', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.064', 'groupId': 'OG000'}, {'value': '-0.02', 'spread': '0.062', 'groupId': 'OG001'}, {'value': '-0.02', 'spread': '0.063', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.076', 'groupId': 'OG000'}, {'value': '-0.01', 'spread': '0.073', 'groupId': 'OG001'}, {'value': '-0.02', 'spread': '0.075', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '129', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.078', 'groupId': 'OG000'}, {'value': '-0.01', 'spread': '0.057', 'groupId': 'OG001'}, {'value': '-0.02', 'spread': '0.070', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Creatinine Clearance (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.08', 'groupId': 'OG000'}, {'value': '0.00', 'groupId': 'OG001'}, {'value': '-0.04', 'spread': '0.059', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.17', 'groupId': 'OG001'}, {'value': '-0.17', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'mL/sec/1.73m^2', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Homocysteine (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '105', 'groupId': 'OG000'}, {'value': '95', 'groupId': 'OG001'}, {'value': '200', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '3.07', 'spread': '5.301', 'groupId': 'OG000'}, {'value': '6.70', 'spread': '11.040', 'groupId': 'OG001'}, {'value': '4.79', 'spread': '8.692', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '76', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '137', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.22', 'spread': '7.549', 'groupId': 'OG000'}, {'value': '6.69', 'spread': '6.306', 'groupId': 'OG001'}, {'value': '5.32', 'spread': '7.106', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '52', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.88', 'spread': '6.103', 'groupId': 'OG000'}, {'value': '7.24', 'spread': '8.687', 'groupId': 'OG001'}, {'value': '5.86', 'spread': '7.351', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'µmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Vitamin B6 (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '104', 'groupId': 'OG000'}, {'value': '94', 'groupId': 'OG001'}, {'value': '198', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.30', 'spread': '129.306', 'groupId': 'OG000'}, {'value': '4.68', 'spread': '87.199', 'groupId': 'OG001'}, {'value': '2.38', 'spread': '111.069', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '76', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '138', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-4.50', 'spread': '89.013', 'groupId': 'OG000'}, {'value': '14.10', 'spread': '103.462', 'groupId': 'OG001'}, {'value': '3.86', 'spread': '95.865', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.32', 'spread': '124.059', 'groupId': 'OG000'}, {'value': '44.30', 'spread': '124.456', 'groupId': 'OG001'}, {'value': '18.95', 'spread': '125.703', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'nmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Vitamin B12 (Clinical Chemistry): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': '-ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '104', 'groupId': 'OG000'}, {'value': '94', 'groupId': 'OG001'}, {'value': '198', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-229.58', 'spread': '1349.008', 'groupId': 'OG000'}, {'value': '-206.30', 'spread': '2217.016', 'groupId': 'OG001'}, {'value': '-218.53', 'spread': '1808.859', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '76', 'groupId': 'OG000'}, {'value': '63', 'groupId': 'OG001'}, {'value': '139', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-147.38', 'spread': '845.662', 'groupId': 'OG000'}, {'value': '-143.30', 'spread': '1033.488', 'groupId': 'OG001'}, {'value': '-145.53', 'spread': '931.955', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '128', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-268.44', 'spread': '1684.785', 'groupId': 'OG000'}, {'value': '-212.84', 'spread': '1096.656', 'groupId': 'OG001'}, {'value': '-244.98', 'spread': '1460.902', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'pmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'pH (Urinalysis): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '98', 'groupId': 'OG000'}, {'value': '88', 'groupId': 'OG001'}, {'value': '186', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.07', 'spread': '0.601', 'groupId': 'OG000'}, {'value': '0.19', 'spread': '0.575', 'groupId': 'OG001'}, {'value': '0.13', 'spread': '0.590', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.20', 'spread': '0.537', 'groupId': 'OG000'}, {'value': '0.24', 'spread': '0.560', 'groupId': 'OG001'}, {'value': '0.22', 'spread': '0.546', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '67', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '121', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.13', 'spread': '0.566', 'groupId': 'OG000'}, {'value': '0.31', 'spread': '0.617', 'groupId': 'OG001'}, {'value': '0.21', 'spread': '0.594', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.18', 'spread': '0.682', 'groupId': 'OG000'}, {'value': '0.20', 'spread': '0.537', 'groupId': 'OG001'}, {'value': '0.19', 'spread': '0.620', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'no units', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Specific Gravity (Urinalysis): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '98', 'groupId': 'OG000'}, {'value': '88', 'groupId': 'OG001'}, {'value': '186', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.009', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.007', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.008', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.009', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.009', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.009', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '122', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.009', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.009', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.009', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '56', 'groupId': 'OG001'}, {'value': '127', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.010', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.009', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.009', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.', 'unitOfMeasure': 'No units', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '128', 'groupId': 'OG000'}, {'value': '112', 'groupId': 'OG001'}, {'value': '240', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 1- orthostatic', 'denoms': [{'units': 'Participants', 'counts': [{'value': '119', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '225', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'spread': '12.00', 'groupId': 'OG000'}, {'value': '3.5', 'spread': '16.01', 'groupId': 'OG001'}, {'value': '0.9', 'spread': '14.22', 'groupId': 'OG002'}]}]}, {'title': 'Week 6- orthostatic', 'denoms': [{'units': 'Participants', 'counts': [{'value': '97', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '186', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'spread': '11.85', 'groupId': 'OG000'}, {'value': '2.6', 'spread': '17.33', 'groupId': 'OG001'}, {'value': '0.5', 'spread': '14.83', 'groupId': 'OG002'}]}]}, {'title': 'Week 26- orthostatic', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '16.25', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '14.38', 'groupId': 'OG001'}, {'value': '-1.4', 'spread': '15.38', 'groupId': 'OG002'}]}]}, {'title': 'Week 52- orthostatic', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '128', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.3', 'spread': '14.59', 'groupId': 'OG000'}, {'value': '0.7', 'spread': '13.75', 'groupId': 'OG001'}, {'value': '-0.4', 'spread': '14.19', 'groupId': 'OG002'}]}]}, {'title': 'Week 1- standing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '122', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '228', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.3', 'spread': '17.05', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '25.50', 'groupId': 'OG001'}, {'value': '-1.9', 'spread': '21.35', 'groupId': 'OG002'}]}]}, {'title': 'Week 6- standing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '90', 'groupId': 'OG001'}, {'value': '189', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.9', 'spread': '18.32', 'groupId': 'OG000'}, {'value': '-3.1', 'spread': '25.89', 'groupId': 'OG001'}, {'value': '-3.0', 'spread': '22.19', 'groupId': 'OG002'}]}]}, {'title': 'Week 26- standing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '132', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-4.7', 'spread': '19.23', 'groupId': 'OG000'}, {'value': '-4.0', 'spread': '21.01', 'groupId': 'OG001'}, {'value': '-4.4', 'spread': '20.00', 'groupId': 'OG002'}]}]}, {'title': 'Week 52- standing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.9', 'spread': '19.81', 'groupId': 'OG000'}, {'value': '-1.5', 'spread': '20.91', 'groupId': 'OG001'}, {'value': '-2.8', 'spread': '20.26', 'groupId': 'OG002'}]}]}, {'title': 'Week 2- supine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '121', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '230', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'spread': '16.75', 'groupId': 'OG000'}, {'value': '-4.5', 'spread': '21.94', 'groupId': 'OG001'}, {'value': '-2.7', 'spread': '19.42', 'groupId': 'OG002'}]}]}, {'title': 'Week 4- supine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '188', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.2', 'spread': '16.67', 'groupId': 'OG000'}, {'value': '-6.7', 'spread': '22.99', 'groupId': 'OG001'}, {'value': '-3.8', 'spread': '20.05', 'groupId': 'OG002'}]}]}, {'title': 'Week 13- supine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '29', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '46', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-4.0', 'spread': '18.34', 'groupId': 'OG000'}, {'value': '-1.8', 'spread': '24.89', 'groupId': 'OG001'}, {'value': '-3.2', 'spread': '20.75', 'groupId': 'OG002'}]}]}, {'title': 'Week 39- supine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '77', 'groupId': 'OG000'}, {'value': '66', 'groupId': 'OG001'}, {'value': '143', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.7', 'spread': '19.12', 'groupId': 'OG000'}, {'value': '-1.8', 'spread': '22.08', 'groupId': 'OG001'}, {'value': '-1.7', 'spread': '20.47', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)', 'description': 'Orthostatic blood pressure was measured after the participant had been supine (lying down with their face up) for at least 5 minutes and then, after the participant had been standing for 2 minutes. When vital sign measurements were scheduled at the same time as a blood collection, vital sign measurements were obtained prior to blood collection.', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '128', 'groupId': 'OG000'}, {'value': '112', 'groupId': 'OG001'}, {'value': '240', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 1- orthostatic', 'denoms': [{'units': 'Participants', 'counts': [{'value': '119', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '225', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.9', 'spread': '10.61', 'groupId': 'OG000'}, {'value': '-0.7', 'spread': '13.27', 'groupId': 'OG001'}, {'value': '-1.3', 'spread': '11.92', 'groupId': 'OG002'}]}]}, {'title': 'Week 6- orthostatic', 'denoms': [{'units': 'Participants', 'counts': [{'value': '97', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '186', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '10.91', 'groupId': 'OG000'}, {'value': '-0.6', 'spread': '10.00', 'groupId': 'OG001'}, {'value': '-0.3', 'spread': '10.46', 'groupId': 'OG002'}]}]}, {'title': 'Week 26- orthostatic', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.7', 'spread': '12.99', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '10.16', 'groupId': 'OG001'}, {'value': '-0.7', 'spread': '11.75', 'groupId': 'OG002'}]}]}, {'title': 'Week 52- orthostatic', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '128', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'spread': '10.44', 'groupId': 'OG000'}, {'value': '0.8', 'spread': '11.42', 'groupId': 'OG001'}, {'value': '-0.4', 'spread': '10.91', 'groupId': 'OG002'}]}]}, {'title': 'Week 1- standing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '122', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '228', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.6', 'spread': '12.00', 'groupId': 'OG000'}, {'value': '-2.1', 'spread': '13.87', 'groupId': 'OG001'}, {'value': '-2.4', 'spread': '12.88', 'groupId': 'OG002'}]}]}, {'title': 'Week 6- standing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '90', 'groupId': 'OG001'}, {'value': '189', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '12.27', 'groupId': 'OG000'}, {'value': '-2.2', 'spread': '14.76', 'groupId': 'OG001'}, {'value': '-1.5', 'spread': '13.50', 'groupId': 'OG002'}]}]}, {'title': 'Week 26- standing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '132', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-4.0', 'spread': '12.20', 'groupId': 'OG000'}, {'value': '-1.2', 'spread': '14.67', 'groupId': 'OG001'}, {'value': '-2.7', 'spread': '13.42', 'groupId': 'OG002'}]}]}, {'title': 'Week 52- standing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.7', 'spread': '12.55', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '12.01', 'groupId': 'OG001'}, {'value': '-0.4', 'spread': '12.34', 'groupId': 'OG002'}]}]}, {'title': 'Week 2- supine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '121', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '230', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '12.46', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '13.46', 'groupId': 'OG001'}, {'value': '-1.2', 'spread': '12.91', 'groupId': 'OG002'}]}]}, {'title': 'Week 4- supine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '188', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.4', 'spread': '12.06', 'groupId': 'OG000'}, {'value': '-2.1', 'spread': '12.80', 'groupId': 'OG001'}, {'value': '-1.7', 'spread': '12.38', 'groupId': 'OG002'}]}]}, {'title': 'Week 13- supine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '29', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '46', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.6', 'spread': '12.52', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '9.59', 'groupId': 'OG001'}, {'value': '-1.8', 'spread': '11.46', 'groupId': 'OG002'}]}]}, {'title': 'Week 39- supine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '77', 'groupId': 'OG000'}, {'value': '66', 'groupId': 'OG001'}, {'value': '143', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '12.16', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '12.77', 'groupId': 'OG001'}, {'value': '0.2', 'spread': '12.40', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)', 'description': 'Orthostatic blood pressure was measured after the participant had been supine (lying down with their face up) for at least 5 minutes and then, after the participant had been standing for 2 minutes. When vital sign measurements were scheduled at the same time as a blood collection, vital sign measurements were obtained prior to blood collection.', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '128', 'groupId': 'OG000'}, {'value': '112', 'groupId': 'OG001'}, {'value': '240', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 1- orthostatic', 'denoms': [{'units': 'Participants', 'counts': [{'value': '119', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '225', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'spread': '8.49', 'groupId': 'OG000'}, {'value': '-1.8', 'spread': '10.49', 'groupId': 'OG001'}, {'value': '-1.6', 'spread': '9.46', 'groupId': 'OG002'}]}]}, {'title': 'Week 6- orthostatic', 'denoms': [{'units': 'Participants', 'counts': [{'value': '97', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '186', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '10.86', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '10.16', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '10.51', 'groupId': 'OG002'}]}]}, {'title': 'Week 26- orthostatic', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.9', 'spread': '8.90', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '9.32', 'groupId': 'OG001'}, {'value': '-0.4', 'spread': '9.08', 'groupId': 'OG002'}]}]}, {'title': 'Week 52- orthostatic', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '128', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '9.72', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '8.55', 'groupId': 'OG001'}, {'value': '0.0', 'spread': '9.19', 'groupId': 'OG002'}]}]}, {'title': 'Week 1- standing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '122', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '228', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-5.1', 'spread': '11.43', 'groupId': 'OG000'}, {'value': '-2.6', 'spread': '12.50', 'groupId': 'OG001'}, {'value': '-3.9', 'spread': '11.98', 'groupId': 'OG002'}]}]}, {'title': 'Week 6- standing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '90', 'groupId': 'OG001'}, {'value': '189', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.1', 'spread': '12.45', 'groupId': 'OG000'}, {'value': '-3.0', 'spread': '12.23', 'groupId': 'OG001'}, {'value': '-3.1', 'spread': '12.31', 'groupId': 'OG002'}]}]}, {'title': 'Week 26- standing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '132', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.9', 'spread': '12.29', 'groupId': 'OG000'}, {'value': '-2.4', 'spread': '12.43', 'groupId': 'OG001'}, {'value': '-2.7', 'spread': '12.31', 'groupId': 'OG002'}]}]}, {'title': 'Week 52- standing', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.8', 'spread': '12.88', 'groupId': 'OG000'}, {'value': '-4.3', 'spread': '11.56', 'groupId': 'OG001'}, {'value': '-4.0', 'spread': '12.27', 'groupId': 'OG002'}]}]}, {'title': 'Week 2- supine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '121', 'groupId': 'OG000'}, {'value': '109', 'groupId': 'OG001'}, {'value': '230', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.3', 'spread': '10.05', 'groupId': 'OG000'}, {'value': '-0.6', 'spread': '11.10', 'groupId': 'OG001'}, {'value': '-2.0', 'spread': '10.62', 'groupId': 'OG002'}]}]}, {'title': 'Week 4- supine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '188', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.6', 'spread': '10.06', 'groupId': 'OG000'}, {'value': '-3.3', 'spread': '12.60', 'groupId': 'OG001'}, {'value': '-3.0', 'spread': '11.31', 'groupId': 'OG002'}]}]}, {'title': 'Week 13- supine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '29', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '46', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.1', 'spread': '11.72', 'groupId': 'OG000'}, {'value': '-4.8', 'spread': '7.60', 'groupId': 'OG001'}, {'value': '-1.1', 'spread': '10.68', 'groupId': 'OG002'}]}]}, {'title': 'Week 39- supine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '77', 'groupId': 'OG000'}, {'value': '66', 'groupId': 'OG001'}, {'value': '143', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.7', 'spread': '11.76', 'groupId': 'OG000'}, {'value': '-3.2', 'spread': '11.16', 'groupId': 'OG001'}, {'value': '-3.4', 'spread': '11.45', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)', 'description': 'Orthostatic pulse rate was measured after the participant had been supine (lying down with their face up) for at least 5 minutes and then, after the participant had been standing for 2 minutes. When vital sign measurements were scheduled at the same time as a blood collection, vital sign measurements were obtained prior to blood collection.', 'unitOfMeasure': 'beats/minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Electrocardiogram (ECG) Mean Heart Rate: Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Day 1 (postdose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}, {'value': '237', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.1', 'spread': '9.51', 'groupId': 'OG000'}, {'value': '2.2', 'spread': '9.76', 'groupId': 'OG001'}, {'value': '2.1', 'spread': '9.61', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '88', 'groupId': 'OG001'}, {'value': '188', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.3', 'spread': '8.60', 'groupId': 'OG000'}, {'value': '-2.2', 'spread': '10.28', 'groupId': 'OG001'}, {'value': '-2.2', 'spread': '9.40', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '131', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.7', 'spread': '9.51', 'groupId': 'OG000'}, {'value': '-0.7', 'spread': '11.36', 'groupId': 'OG001'}, {'value': '-2.3', 'spread': '10.44', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.', 'unitOfMeasure': 'beats/minute', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Electrocardiogram (ECG) Aggregate PR Interval: Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '130', 'groupId': 'OG000'}, {'value': '107', 'groupId': 'OG001'}, {'value': '237', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Day 1 (postdose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '125', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '230', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.4', 'spread': '14.08', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '13.76', 'groupId': 'OG001'}, {'value': '0.2', 'spread': '13.91', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '84', 'groupId': 'OG001'}, {'value': '183', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '13.97', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '16.84', 'groupId': 'OG001'}, {'value': '0.8', 'spread': '15.31', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '126', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.5', 'spread': '12.48', 'groupId': 'OG000'}, {'value': '-5.8', 'spread': '20.54', 'groupId': 'OG001'}, {'value': '-1.6', 'spread': '16.75', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.', 'unitOfMeasure': 'milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Electrocardiogram (ECG) Aggregate QRS Duration: Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Day 1 (postdose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}, {'value': '237', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.3', 'spread': '7.32', 'groupId': 'OG000'}, {'value': '-0.8', 'spread': '8.41', 'groupId': 'OG001'}, {'value': '-1.6', 'spread': '7.87', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '88', 'groupId': 'OG001'}, {'value': '188', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '8.32', 'groupId': 'OG000'}, {'value': '1.6', 'spread': '8.96', 'groupId': 'OG001'}, {'value': '0.5', 'spread': '8.67', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '6.85', 'groupId': 'OG000'}, {'value': '0.9', 'spread': '7.29', 'groupId': 'OG001'}, {'value': '0.3', 'spread': '7.04', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.', 'unitOfMeasure': 'milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Electrocardiogram (ECG) Aggregate QT Interval: Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Day 1 (postdose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}, {'value': '237', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-5.3', 'spread': '20.72', 'groupId': 'OG000'}, {'value': '-4.2', 'spread': '23.99', 'groupId': 'OG001'}, {'value': '-4.8', 'spread': '22.27', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '88', 'groupId': 'OG001'}, {'value': '187', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '6.4', 'spread': '20.96', 'groupId': 'OG000'}, {'value': '6.4', 'spread': '24.61', 'groupId': 'OG001'}, {'value': '6.4', 'spread': '22.69', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '9.8', 'spread': '24.66', 'groupId': 'OG000'}, {'value': '4.3', 'spread': '26.24', 'groupId': 'OG001'}, {'value': '7.3', 'spread': '25.42', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.', 'unitOfMeasure': 'milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Electrocardiogram (ECG) Aggregate QTcB Interval: Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Day 1 (postdose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}, {'value': '237', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.2', 'spread': '17.96', 'groupId': 'OG000'}, {'value': '2.0', 'spread': '17.21', 'groupId': 'OG001'}, {'value': '1.6', 'spread': '17.58', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '88', 'groupId': 'OG001'}, {'value': '187', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '19.91', 'groupId': 'OG000'}, {'value': '0.6', 'spread': '18.34', 'groupId': 'OG001'}, {'value': '0.8', 'spread': '19.14', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '20.84', 'groupId': 'OG000'}, {'value': '2.1', 'spread': '18.33', 'groupId': 'OG001'}, {'value': '0.9', 'spread': '19.72', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.', 'unitOfMeasure': 'milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Electrocardiogram (ECG) Aggregate QTcF Interval: Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Day 1 (postdose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}, {'value': '237', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'spread': '14.03', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '15.75', 'groupId': 'OG001'}, {'value': '-0.6', 'spread': '14.84', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '99', 'groupId': 'OG000'}, {'value': '88', 'groupId': 'OG001'}, {'value': '187', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '3.1', 'spread': '16.49', 'groupId': 'OG000'}, {'value': '2.6', 'spread': '15.63', 'groupId': 'OG001'}, {'value': '2.9', 'spread': '16.05', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '3.4', 'spread': '18.05', 'groupId': 'OG000'}, {'value': '2.9', 'spread': '15.40', 'groupId': 'OG001'}, {'value': '3.2', 'spread': '16.86', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.', 'unitOfMeasure': 'milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'PRIMARY', 'title': 'Electrocardiogram (ECG) Aggregate RR Interval: Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Day 1 (postdose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '111', 'groupId': 'OG001'}, {'value': '237', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-30.7', 'spread': '122.48', 'groupId': 'OG000'}, {'value': '-28.3', 'spread': '113.02', 'groupId': 'OG001'}, {'value': '-29.6', 'spread': '117.90', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '100', 'groupId': 'OG000'}, {'value': '88', 'groupId': 'OG001'}, {'value': '188', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '22.6', 'spread': '112.51', 'groupId': 'OG000'}, {'value': '26.1', 'spread': '129.35', 'groupId': 'OG001'}, {'value': '24.2', 'spread': '120.37', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '131', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '41.8', 'spread': '122.96', 'groupId': 'OG000'}, {'value': '9.4', 'spread': '141.91', 'groupId': 'OG001'}, {'value': '27.5', 'spread': '132.15', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.', 'unitOfMeasure': 'milliseconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion with available data'}, {'type': 'SECONDARY', 'title': 'Average Daily Normalized "Off" Time: Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '110', 'groupId': 'OG001'}, {'value': '236', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '120', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '225', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.04', 'spread': '3.51', 'groupId': 'OG000'}, {'value': '-1.84', 'spread': '3.88', 'groupId': 'OG001'}, {'value': '-1.95', 'spread': '3.68', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '110', 'groupId': 'OG000'}, {'value': '95', 'groupId': 'OG001'}, {'value': '205', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.43', 'spread': '3.66', 'groupId': 'OG000'}, {'value': '-2.36', 'spread': '3.56', 'groupId': 'OG001'}, {'value': '-2.40', 'spread': '3.61', 'groupId': 'OG002'}]}]}, {'title': 'Week 13', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '114', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.50', 'spread': '3.83', 'groupId': 'OG000'}, {'value': '-2.34', 'spread': '3.57', 'groupId': 'OG001'}, {'value': '-2.43', 'spread': '3.70', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '131', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.31', 'spread': '3.36', 'groupId': 'OG000'}, {'value': '-3.38', 'spread': '3.15', 'groupId': 'OG001'}, {'value': '-3.35', 'spread': '3.25', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '122', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.25', 'spread': '3.43', 'groupId': 'OG000'}, {'value': '-3.52', 'spread': '2.92', 'groupId': 'OG001'}, {'value': '-3.37', 'spread': '3.21', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '62', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.43', 'spread': '3.16', 'groupId': 'OG000'}, {'value': '-3.59', 'spread': '3.11', 'groupId': 'OG001'}, {'value': '-3.51', 'spread': '3.12', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'Week 26 vs Baseline'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 1, 6, 13, 26, 39, and 52', 'description': 'Upon awakening and every 30 minutes during their normal waking time, participants recorded their state in the Parkinson\'s Disease Diary (PD Diary) for 2 consecutive days prior to study visits.\n\n"Off" time is defined as periods of poor mobility, tremor, slowness, and stiffness. The daily "On" and "Off" times were normalized to a typical waking day (16 hours) to account for different sleep patterns across participants. When "Off" was the first morning symptom upon awakening, this was considered morning akinesia in this study.\n\nBaseline value is defined as the average of normalized "Off" time collected over the 2 PD Diary days before the Enrollment visit. Negative changes from Baseline indicate improvement.', 'unitOfMeasure': 'hours', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure'}, {'type': 'SECONDARY', 'title': 'Average Daily Normalized "On" Time With Troublesome Dyskinesia: Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '110', 'groupId': 'OG001'}, {'value': '236', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '120', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '225', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.00', 'spread': '2.10', 'groupId': 'OG000'}, {'value': '0.11', 'spread': '1.64', 'groupId': 'OG001'}, {'value': '0.05', 'spread': '1.89', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '110', 'groupId': 'OG000'}, {'value': '95', 'groupId': 'OG001'}, {'value': '205', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.56', 'spread': '1.95', 'groupId': 'OG000'}, {'value': '-0.23', 'spread': '1.05', 'groupId': 'OG001'}, {'value': '-0.41', 'spread': '1.60', 'groupId': 'OG002'}]}]}, {'title': 'Week 13', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '114', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.60', 'spread': '1.72', 'groupId': 'OG000'}, {'value': '-0.38', 'spread': '1.04', 'groupId': 'OG001'}, {'value': '-0.50', 'spread': '1.45', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '131', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.61', 'spread': '1.95', 'groupId': 'OG000'}, {'value': '-0.27', 'spread': '1.73', 'groupId': 'OG001'}, {'value': '-0.45', 'spread': '1.85', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '122', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.49', 'spread': '1.07', 'groupId': 'OG000'}, {'value': '-0.17', 'spread': '1.59', 'groupId': 'OG001'}, {'value': '-0.35', 'spread': '1.33', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '62', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.64', 'spread': '1.73', 'groupId': 'OG000'}, {'value': '0.17', 'spread': '2.53', 'groupId': 'OG001'}, {'value': '-0.27', 'spread': '2.16', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '>0.999', 'groupIds': ['OG000'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.5095', 'groupIds': ['OG001'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.6962', 'groupIds': ['OG002'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0035', 'groupIds': ['OG000'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0324', 'groupIds': ['OG001'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0072', 'groupIds': ['OG000'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0129', 'groupIds': ['OG001'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0119', 'groupIds': ['OG000'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.2200', 'groupIds': ['OG001'], 'pValueComment': 'A paired-sample t-test was performed to test the change from Baseline.', 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '=0.0063', 'groupIds': ['OG002'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.4331', 'groupIds': ['OG001'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0045', 'groupIds': ['OG002'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0049', 'groupIds': ['OG000'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'Wilcoxon (Mann-Whitney)', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.6312', 'groupIds': ['OG001'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.1892', 'groupIds': ['OG002'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 1, 6, 13, 26, 39, and 52', 'description': 'Upon awakening and every 30 minutes during their normal waking time, participants recorded their state in the Parkinson\'s Disease Diary (PD Diary) for 2 consecutive days prior to study visits.\n\n"On" time is defined as periods of good motor symptom control. The daily "On" and "Off" times were normalized to a typical waking day (16 hours) to account for different sleep patterns across participants.\n\nBaseline value is defined as the average of normalized "On" time with troublesome dyskinesia collected over the 2 PD Diary days before the Enrollment visit. Negative changes from Baseline indicate improvement.', 'unitOfMeasure': 'hours', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure'}, {'type': 'SECONDARY', 'title': 'Average Daily Normalized "On" Time Without Troublesome Dyskinesia: Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '126', 'groupId': 'OG000'}, {'value': '110', 'groupId': 'OG001'}, {'value': '236', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '120', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '225', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.04', 'spread': '3.55', 'groupId': 'OG000'}, {'value': '1.74', 'spread': '4.04', 'groupId': 'OG001'}, {'value': '1.90', 'spread': '3.78', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '110', 'groupId': 'OG000'}, {'value': '95', 'groupId': 'OG001'}, {'value': '205', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.99', 'spread': '3.60', 'groupId': 'OG000'}, {'value': '2.60', 'spread': '3.58', 'groupId': 'OG001'}, {'value': '2.81', 'spread': '3.59', 'groupId': 'OG002'}]}]}, {'title': 'Week 13', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '114', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '3.10', 'spread': '3.32', 'groupId': 'OG000'}, {'value': '2.72', 'spread': '3.68', 'groupId': 'OG001'}, {'value': '2.93', 'spread': '3.48', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '131', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '3.92', 'spread': '3.76', 'groupId': 'OG000'}, {'value': '3.65', 'spread': '3.31', 'groupId': 'OG001'}, {'value': '3.79', 'spread': '3.55', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '122', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '3.74', 'spread': '3.40', 'groupId': 'OG000'}, {'value': '3.69', 'spread': '3.32', 'groupId': 'OG001'}, {'value': '3.71', 'spread': '3.35', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '62', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '116', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.08', 'spread': '3.28', 'groupId': 'OG000'}, {'value': '3.43', 'spread': '3.28', 'groupId': 'OG001'}, {'value': '3.77', 'spread': '3.28', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 1, 6, 13, 26, 39, and 52', 'description': 'Upon awakening and every 30 minutes during their normal waking time, participants recorded their state in the Parkinson\'s Disease Diary (PD Diary) for 2 consecutive days prior to study visits.\n\n"On" time is defined as periods of good motor symptom control. The daily "On" and "Off" times were normalized to a typical waking day (16 hours) to account for different sleep patterns across participants.\n\nBaseline value is defined as the average of normalized "On" time without troublesome dyskinesia collected over the 2 PD Diary days before the Enrollment visit. Positive changes from Baseline indicate improvement.', 'unitOfMeasure': 'hours', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure'}, {'type': 'SECONDARY', 'title': "Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study", 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '120', 'groupId': 'OG000'}, {'value': '102', 'groupId': 'OG001'}, {'value': '222', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.6', 'spread': '4.28', 'groupId': 'OG000'}, {'value': '-1.8', 'spread': '3.61', 'groupId': 'OG001'}, {'value': '-2.3', 'spread': '4.00', 'groupId': 'OG002'}]}]}, {'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '120', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '226', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.6', 'spread': '5.84', 'groupId': 'OG000'}, {'value': '-3.3', 'spread': '5.50', 'groupId': 'OG001'}, {'value': '-2.9', 'spread': '5.68', 'groupId': 'OG002'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '117', 'groupId': 'OG000'}, {'value': '95', 'groupId': 'OG001'}, {'value': '212', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'spread': '5.29', 'groupId': 'OG000'}, {'value': '-2.1', 'spread': '5.10', 'groupId': 'OG001'}, {'value': '-2.3', 'spread': '5.20', 'groupId': 'OG002'}]}]}, {'title': 'Week 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '107', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '203', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.3', 'spread': '5.65', 'groupId': 'OG000'}, {'value': '-2.9', 'spread': '5.91', 'groupId': 'OG001'}, {'value': '-2.6', 'spread': '5.77', 'groupId': 'OG002'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '109', 'groupId': 'OG000'}, {'value': '94', 'groupId': 'OG001'}, {'value': '203', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.7', 'spread': '6.22', 'groupId': 'OG000'}, {'value': '-3.0', 'spread': '5.42', 'groupId': 'OG001'}, {'value': '-2.3', 'spread': '5.88', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '104', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '193', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '7.00', 'groupId': 'OG000'}, {'value': '-1.7', 'spread': '5.15', 'groupId': 'OG001'}, {'value': '-1.4', 'spread': '6.21', 'groupId': 'OG002'}]}]}, {'title': 'Week 13', 'denoms': [{'units': 'Participants', 'counts': [{'value': '93', 'groupId': 'OG000'}, {'value': '77', 'groupId': 'OG001'}, {'value': '170', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.8', 'spread': '5.80', 'groupId': 'OG000'}, {'value': '-1.7', 'spread': '5.59', 'groupId': 'OG001'}, {'value': '-1.7', 'spread': '5.69', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '79', 'groupId': 'OG000'}, {'value': '69', 'groupId': 'OG001'}, {'value': '148', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '5.01', 'groupId': 'OG000'}, {'value': '-0.7', 'spread': '5.88', 'groupId': 'OG001'}, {'value': '-0.9', 'spread': '5.42', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '60', 'groupId': 'OG001'}, {'value': '135', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '5.64', 'groupId': 'OG000'}, {'value': '0.1', 'spread': '6.00', 'groupId': 'OG001'}, {'value': '-0.4', 'spread': '5.80', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '133', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '5.30', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '6.22', 'groupId': 'OG001'}, {'value': '-0.9', 'spread': '5.71', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Day 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Day 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Day 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 3 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 3 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 3 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0042', 'groupIds': ['OG000'], 'groupDescription': 'Week 4 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 4 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 4 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.1135', 'groupIds': ['OG000'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0029', 'groupIds': ['OG001'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0026', 'groupIds': ['OG002'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0034', 'groupIds': ['OG000'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0103', 'groupIds': ['OG001'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0493', 'groupIds': ['OG000'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.3003', 'groupIds': ['OG001'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0354', 'groupIds': ['OG002'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.2553', 'groupIds': ['OG000'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.8640', 'groupIds': ['OG001'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.4774', 'groupIds': ['OG002'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.3865', 'groupIds': ['OG000'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '0.1186', 'groupIds': ['OG001'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0830', 'groupIds': ['OG002'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 13, 26, 39, and 52', 'description': "The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part I assesses the participant's non-motor aspects of experiences of daily living (nM-EDL) with 13 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part I scores range from 0 to 52, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure'}, {'type': 'SECONDARY', 'title': "Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score: Change From Baseline to End of Study", 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '120', 'groupId': 'OG000'}, {'value': '102', 'groupId': 'OG001'}, {'value': '222', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.8', 'spread': '4.55', 'groupId': 'OG000'}, {'value': '-1.2', 'spread': '4.25', 'groupId': 'OG001'}, {'value': '-2.1', 'spread': '4.47', 'groupId': 'OG002'}]}]}, {'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '120', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '226', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.6', 'spread': '4.98', 'groupId': 'OG000'}, {'value': '-3.9', 'spread': '5.85', 'groupId': 'OG001'}, {'value': '-3.7', 'spread': '5.40', 'groupId': 'OG002'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '117', 'groupId': 'OG000'}, {'value': '95', 'groupId': 'OG001'}, {'value': '212', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.3', 'spread': '6.06', 'groupId': 'OG000'}, {'value': '-3.4', 'spread': '6.53', 'groupId': 'OG001'}, {'value': '-3.3', 'spread': '6.26', 'groupId': 'OG002'}]}]}, {'title': 'Week 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '107', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '203', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.5', 'spread': '5.83', 'groupId': 'OG000'}, {'value': '-3.9', 'spread': '6.63', 'groupId': 'OG001'}, {'value': '-3.7', 'spread': '6.21', 'groupId': 'OG002'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '109', 'groupId': 'OG000'}, {'value': '84', 'groupId': 'OG001'}, {'value': '203', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.6', 'spread': '5.50', 'groupId': 'OG000'}, {'value': '-4.9', 'spread': '6.32', 'groupId': 'OG001'}, {'value': '-3.7', 'spread': '5.98', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '104', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '193', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'spread': '6.60', 'groupId': 'OG000'}, {'value': '-4.2', 'spread': '6.09', 'groupId': 'OG001'}, {'value': '-3.3', 'spread': '6.41', 'groupId': 'OG002'}]}]}, {'title': 'Week 13', 'denoms': [{'units': 'Participants', 'counts': [{'value': '93', 'groupId': 'OG000'}, {'value': '77', 'groupId': 'OG001'}, {'value': '170', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.2', 'spread': '6.44', 'groupId': 'OG000'}, {'value': '-4.3', 'spread': '6.57', 'groupId': 'OG001'}, {'value': '-3.7', 'spread': '6.50', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '79', 'groupId': 'OG000'}, {'value': '69', 'groupId': 'OG001'}, {'value': '148', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.6', 'spread': '6.27', 'groupId': 'OG000'}, {'value': '-3.9', 'spread': '7.05', 'groupId': 'OG001'}, {'value': '-3.2', 'spread': '6.65', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '60', 'groupId': 'OG001'}, {'value': '135', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.6', 'spread': '6.32', 'groupId': 'OG000'}, {'value': '-4.0', 'spread': '6.93', 'groupId': 'OG001'}, {'value': '-3.2', 'spread': '6.61', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '133', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.1', 'spread': '6.94', 'groupId': 'OG000'}, {'value': '-4.5', 'spread': '7.07', 'groupId': 'OG001'}, {'value': '-3.2', 'spread': '7.07', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Day 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0041', 'groupIds': ['OG001'], 'groupDescription': 'Day 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Day 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 3 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 3 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 3 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 4 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 4 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 4 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0091', 'groupIds': ['OG000'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 13, 26, 39, and 52', 'description': "The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part II assesses the participant's motor experiences of daily living (M-EDL) with 13 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part II scores range from 0 to 52, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure'}, {'type': 'SECONDARY', 'title': "Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score: Change From Baseline to End of Study", 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '120', 'groupId': 'OG000'}, {'value': '102', 'groupId': 'OG001'}, {'value': '222', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '8.45', 'groupId': 'OG000'}, {'value': '-0.8', 'spread': '9.20', 'groupId': 'OG001'}, {'value': '-0.7', 'spread': '8.78', 'groupId': 'OG002'}]}]}, {'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '119', 'groupId': 'OG000'}, {'value': '106', 'groupId': 'OG001'}, {'value': '225', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.0', 'spread': '11.55', 'groupId': 'OG000'}, {'value': '3.8', 'spread': '11.00', 'groupId': 'OG001'}, {'value': '2.8', 'spread': '11.31', 'groupId': 'OG002'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '117', 'groupId': 'OG000'}, {'value': '94', 'groupId': 'OG001'}, {'value': '211', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.1', 'spread': '13.02', 'groupId': 'OG000'}, {'value': '1.4', 'spread': '10.93', 'groupId': 'OG001'}, {'value': '2.9', 'spread': '12.18', 'groupId': 'OG002'}]}]}, {'title': 'Week 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '107', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '203', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '3.9', 'spread': '11.98', 'groupId': 'OG000'}, {'value': '2.2', 'spread': '12.07', 'groupId': 'OG001'}, {'value': '3.1', 'spread': '12.02', 'groupId': 'OG002'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '107', 'groupId': 'OG000'}, {'value': '93', 'groupId': 'OG001'}, {'value': '200', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.7', 'spread': '12.84', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '10.97', 'groupId': 'OG001'}, {'value': '1.5', 'spread': '12.05', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '104', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '193', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.4', 'spread': '13.74', 'groupId': 'OG000'}, {'value': '-0.7', 'spread': '9.58', 'groupId': 'OG001'}, {'value': '0.9', 'spread': '12.07', 'groupId': 'OG002'}]}]}, {'title': 'Week 13', 'denoms': [{'units': 'Participants', 'counts': [{'value': '89', 'groupId': 'OG000'}, {'value': '70', 'groupId': 'OG001'}, {'value': '159', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.4', 'spread': '13.79', 'groupId': 'OG000'}, {'value': '-1.6', 'spread': '11.82', 'groupId': 'OG001'}, {'value': '0.1', 'spread': '13.01', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '139', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.4', 'spread': '12.71', 'groupId': 'OG000'}, {'value': '0.1', 'spread': '11.61', 'groupId': 'OG001'}, {'value': '0.8', 'spread': '12.19', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.9', 'spread': '12.70', 'groupId': 'OG000'}, {'value': '2.3', 'spread': '13.26', 'groupId': 'OG001'}, {'value': '2.1', 'spread': '12.89', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '133', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '12.53', 'groupId': 'OG000'}, {'value': '1.7', 'spread': '13.02', 'groupId': 'OG001'}, {'value': '1.7', 'spread': '12.69', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '=0.4447', 'groupIds': ['OG000'], 'groupDescription': 'Day 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.3567', 'groupIds': ['OG001'], 'groupDescription': 'Day 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.2315', 'groupIds': ['OG002'], 'groupDescription': 'Day 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0667', 'groupIds': ['OG000'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.2033', 'groupIds': ['OG001'], 'groupDescription': 'Week 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0012', 'groupIds': ['OG000'], 'groupDescription': 'Week 3 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0734', 'groupIds': ['OG001'], 'groupDescription': 'Week 3 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 3 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0304', 'groupIds': ['OG000'], 'groupDescription': 'Week 4 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '>0.999', 'groupIds': ['OG001'], 'groupDescription': 'Week 4 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0891', 'groupIds': ['OG002'], 'groupDescription': 'Week 4 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0832', 'groupIds': ['OG000'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.4941', 'groupIds': ['OG001'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.2764', 'groupIds': ['OG002'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.3248', 'groupIds': ['OG000'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.2535', 'groupIds': ['OG001'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.9274', 'groupIds': ['OG002'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.3297', 'groupIds': ['OG000'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.9722', 'groupIds': ['OG001'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.4403', 'groupIds': ['OG002'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.1946', 'groupIds': ['OG000'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.2077', 'groupIds': ['OG001'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0692', 'groupIds': ['OG002'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.2276', 'groupIds': ['OG000'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '0.3369', 'groupIds': ['OG001'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.1218', 'groupIds': ['OG002'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 13, 26, 39, and 52', 'description': "The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part III assesses the participant's motor examination (including Hoehn and Yahr stage) with 33 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part III scores range from 0 to 132, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure'}, {'type': 'SECONDARY', 'title': "Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV Score: Change From Baseline to End of Study", 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '113', 'groupId': 'OG001'}, {'value': '244', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Day 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '117', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}, {'value': '218', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.8', 'spread': '3.57', 'groupId': 'OG000'}, {'value': '-1.1', 'spread': '3.45', 'groupId': 'OG001'}, {'value': '-1.5', 'spread': '3.52', 'groupId': 'OG002'}]}]}, {'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '117', 'groupId': 'OG000'}, {'value': '105', 'groupId': 'OG001'}, {'value': '222', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-1.7', 'spread': '3.86', 'groupId': 'OG000'}, {'value': '-1.7', 'spread': '4.10', 'groupId': 'OG001'}, {'value': '-1.7', 'spread': '3.96', 'groupId': 'OG002'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '115', 'groupId': 'OG000'}, {'value': '93', 'groupId': 'OG001'}, {'value': '208', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'spread': '3.58', 'groupId': 'OG000'}, {'value': '-2.3', 'spread': '3.56', 'groupId': 'OG001'}, {'value': '-2.4', 'spread': '3.57', 'groupId': 'OG002'}]}]}, {'title': 'Week 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '102', 'groupId': 'OG000'}, {'value': '96', 'groupId': 'OG001'}, {'value': '198', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.1', 'spread': '4.06', 'groupId': 'OG000'}, {'value': '-2.3', 'spread': '3.74', 'groupId': 'OG001'}, {'value': '-2.2', 'spread': '3.90', 'groupId': 'OG002'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '106', 'groupId': 'OG000'}, {'value': '94', 'groupId': 'OG001'}, {'value': '200', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.0', 'spread': '3.69', 'groupId': 'OG000'}, {'value': '-2.6', 'spread': '3.78', 'groupId': 'OG001'}, {'value': '-2.8', 'spread': '3.73', 'groupId': 'OG002'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '101', 'groupId': 'OG000'}, {'value': '89', 'groupId': 'OG001'}, {'value': '190', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-2.6', 'spread': '3.34', 'groupId': 'OG000'}, {'value': '-2.8', 'spread': '3.90', 'groupId': 'OG001'}, {'value': '-2.7', 'spread': '3.61', 'groupId': 'OG002'}]}]}, {'title': 'Week 13', 'denoms': [{'units': 'Participants', 'counts': [{'value': '89', 'groupId': 'OG000'}, {'value': '77', 'groupId': 'OG001'}, {'value': '166', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.7', 'spread': '3.47', 'groupId': 'OG000'}, {'value': '-3.3', 'spread': '4.04', 'groupId': 'OG001'}, {'value': '-3.5', 'spread': '3.74', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '77', 'groupId': 'OG000'}, {'value': '69', 'groupId': 'OG001'}, {'value': '146', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.5', 'spread': '3.43', 'groupId': 'OG000'}, {'value': '-3.5', 'spread': '4.12', 'groupId': 'OG001'}, {'value': '-3.5', 'spread': '3.76', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '59', 'groupId': 'OG001'}, {'value': '132', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-3.5', 'spread': '4.06', 'groupId': 'OG000'}, {'value': '-3.5', 'spread': '4.11', 'groupId': 'OG001'}, {'value': '-3.5', 'spread': '4.07', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '130', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-4.1', 'spread': '3.75', 'groupId': 'OG000'}, {'value': '-3.8', 'spread': '4.71', 'groupId': 'OG001'}, {'value': '-3.9', 'spread': '4.19', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Day 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0020', 'groupIds': ['OG001'], 'groupDescription': 'Day 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 1 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Day 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 2 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 3 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 3 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 3 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 4 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 4 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 4 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 13, 26, 39, and 52', 'description': "The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part IV assesses the participant's motor complications with 6 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part IV scores range from 0 to 24, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure'}, {'type': 'SECONDARY', 'title': "Sleep Symptoms as Assessed by the Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score: Change From Baseline to End of Study", 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '112', 'groupId': 'OG001'}, {'value': '243', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '105', 'groupId': 'OG000'}, {'value': '91', 'groupId': 'OG001'}, {'value': '196', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-5.0', 'spread': '11.39', 'groupId': 'OG000'}, {'value': '-7.3', 'spread': '8.81', 'groupId': 'OG001'}, {'value': '-6.1', 'spread': '10.31', 'groupId': 'OG002'}]}]}, {'title': 'Week 13', 'denoms': [{'units': 'Participants', 'counts': [{'value': '93', 'groupId': 'OG000'}, {'value': '77', 'groupId': 'OG001'}, {'value': '170', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-6.9', 'spread': '10.76', 'groupId': 'OG000'}, {'value': '-8.2', 'spread': '8.89', 'groupId': 'OG001'}, {'value': '-7.5', 'spread': '9.94', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '80', 'groupId': 'OG000'}, {'value': '69', 'groupId': 'OG001'}, {'value': '149', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-5.0', 'spread': '13.06', 'groupId': 'OG000'}, {'value': '-8.4', 'spread': '8.07', 'groupId': 'OG001'}, {'value': '-6.6', 'spread': '11.12', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '76', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '137', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-7.0', 'spread': '11.19', 'groupId': 'OG000'}, {'value': '-7.2', 'spread': '9.21', 'groupId': 'OG001'}, {'value': '-7.1', 'spread': '10.32', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '57', 'groupId': 'OG001'}, {'value': '131', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-6.5', 'spread': '12.34', 'groupId': 'OG000'}, {'value': '-8.7', 'spread': '8.19', 'groupId': 'OG001'}, {'value': '-7.5', 'spread': '10.75', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 13, 26, 39, and 52', 'description': "The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \\[never\\] to 4 \\[very often\\] with the exception of Question 1 score ranging from 0 \\[very often\\] to 4 \\[never\\]). Scores are calculated for each of the 3 domains as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Higher scores indicate higher frequency and more severe impact of PD on sleep. Negative changes indicate improvement from Baseline.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure'}, {'type': 'SECONDARY', 'title': "Quality of Life Assessed by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index Score: Change From Baseline to End of Study", 'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'OG000'}, {'value': '112', 'groupId': 'OG001'}, {'value': '243', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '105', 'groupId': 'OG000'}, {'value': '91', 'groupId': 'OG001'}, {'value': '196', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-7.0', 'spread': '14.53', 'groupId': 'OG000'}, {'value': '-8.4', 'spread': '10.53', 'groupId': 'OG001'}, {'value': '-7.6', 'spread': '12.81', 'groupId': 'OG002'}]}]}, {'title': 'Week 13', 'denoms': [{'units': 'Participants', 'counts': [{'value': '93', 'groupId': 'OG000'}, {'value': '77', 'groupId': 'OG001'}, {'value': '170', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-8.3', 'spread': '15.33', 'groupId': 'OG000'}, {'value': '-8.2', 'spread': '11.18', 'groupId': 'OG001'}, {'value': '-8.3', 'spread': '13.57', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '79', 'groupId': 'OG000'}, {'value': '69', 'groupId': 'OG001'}, {'value': '148', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-7.4', 'spread': '13.00', 'groupId': 'OG000'}, {'value': '-7.1', 'spread': '12.27', 'groupId': 'OG001'}, {'value': '-7.3', 'spread': '12.62', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '76', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}, {'value': '137', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-7.8', 'spread': '13.81', 'groupId': 'OG000'}, {'value': '-7.5', 'spread': '13.58', 'groupId': 'OG001'}, {'value': '-7.7', 'spread': '13.66', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '57', 'groupId': 'OG001'}, {'value': '132', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-7.2', 'spread': '14.65', 'groupId': 'OG000'}, {'value': '-7.2', 'spread': '12.35', 'groupId': 'OG001'}, {'value': '-7.2', 'spread': '13.65', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 13, 26, 39, and 52', 'description': "The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable). Higher scores are consistently associated with more severe symptoms of the disease such as tremors and stiffness. The results can be presented in either domain scores or as a summary index score. The full range of the PDQ-39 summary index score is from 0 (no patient-related symptoms/quality of life unaffected) to 100 (highest patient-related symptoms/low quality of life). Negative changes indicate improvement from Baseline.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure'}, {'type': 'SECONDARY', 'title': 'The EuroQol 5-Dimension Questionnaire (EQ-5D-5L) Quality of Life Summary Index: Change From Baseline to End of Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '125', 'groupId': 'OG000'}, {'value': '104', 'groupId': 'OG001'}, {'value': '229', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'OG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'OG002', 'title': 'ABBV-951 All Participants', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period.'}], 'classes': [{'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '93', 'groupId': 'OG000'}, {'value': '82', 'groupId': 'OG001'}, {'value': '175', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.060', 'spread': '0.1921', 'groupId': 'OG000'}, {'value': '0.113', 'spread': '0.1780', 'groupId': 'OG001'}, {'value': '0.085', 'spread': '0.1870', 'groupId': 'OG002'}]}]}, {'title': 'Week 13', 'denoms': [{'units': 'Participants', 'counts': [{'value': '80', 'groupId': 'OG000'}, {'value': '66', 'groupId': 'OG001'}, {'value': '146', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.064', 'spread': '0.2153', 'groupId': 'OG000'}, {'value': '0.122', 'spread': '0.1984', 'groupId': 'OG001'}, {'value': '0.090', 'spread': '0.2092', 'groupId': 'OG002'}]}]}, {'title': 'Week 26', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '128', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.074', 'spread': '0.1771', 'groupId': 'OG000'}, {'value': '0.122', 'spread': '0.1803', 'groupId': 'OG001'}, {'value': '0.096', 'spread': '0.1795', 'groupId': 'OG002'}]}]}, {'title': 'Week 39', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '121', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.075', 'spread': '0.1842', 'groupId': 'OG000'}, {'value': '0.129', 'spread': '0.1995', 'groupId': 'OG001'}, {'value': '0.097', 'spread': '0.1916', 'groupId': 'OG002'}]}]}, {'title': 'Week 52', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '52', 'groupId': 'OG001'}, {'value': '122', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.076', 'spread': '0.2062', 'groupId': 'OG000'}, {'value': '0.126', 'spread': '0.2213', 'groupId': 'OG001'}, {'value': '0.097', 'spread': '0.2134', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '=0.0035', 'groupIds': ['OG000'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 6 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0098', 'groupIds': ['OG000'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 13 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 26 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG000'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 39 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '=0.0030', 'groupIds': ['OG000'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG001'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}, {'pValue': '<0.001', 'groupIds': ['OG002'], 'groupDescription': 'Week 52 vs Baseline', 'statisticalMethod': 'paired-sample t-test', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A paired-sample t-test was performed to test the change from Baseline.'}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 6, 13, 26, 39, and 52', 'description': "The EuroQol 5-dimension questionnaire (EQ-5D-5L) is a standardized non-disease specific instrument for describing and valuing health-related quality of life. The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. The health status is converted to an index value using the country-specific weighted scoring algorithm for the United States (US). The summary index value for the US ranges from a worst score of -0.109 to a best score of 1. An increase in the EQ-5D-5L total score indicates improvement.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set: all participants who received any ABBV-951 infusion and had a Baseline and treatment observation for at least 1 efficacy outcome measure'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'FG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '131'}, {'groupId': 'FG001', 'numSubjects': '113'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '84'}, {'groupId': 'FG001', 'numSubjects': '65'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '47'}, {'groupId': 'FG001', 'numSubjects': '48'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '23'}, {'groupId': 'FG001', 'numSubjects': '25'}]}, {'type': 'Withdrew consent', 'reasons': [{'groupId': 'FG000', 'numSubjects': '16'}, {'groupId': 'FG001', 'numSubjects': '12'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '5'}]}, {'type': 'Difficulty with drug delivery system', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '3'}]}, {'type': 'Other, not specified', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}]}]}], 'preAssignmentDetails': 'All enrolled participants'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '131', 'groupId': 'BG000'}, {'value': '113', 'groupId': 'BG001'}, {'value': '244', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.'}, {'id': 'BG001', 'title': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '63.5', 'spread': '8.87', 'groupId': 'BG000'}, {'value': '64.4', 'spread': '9.54', 'groupId': 'BG001'}, {'value': '63.9', 'spread': '9.18', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '66', 'groupId': 'BG000'}, {'value': '32', 'groupId': 'BG001'}, {'value': '98', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '65', 'groupId': 'BG000'}, {'value': '81', 'groupId': 'BG001'}, {'value': '146', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '12', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '123', 'groupId': 'BG000'}, {'value': '101', 'groupId': 'BG001'}, {'value': '224', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '27', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '34', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '102', 'groupId': 'BG000'}, {'value': '105', 'groupId': 'BG001'}, {'value': '207', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Safety Analysis Set: all participants who received any ABBV-951 infusion'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-02-11', 'size': 5569124, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2023-08-14T12:01', 'hasProtocol': True}, {'date': '2021-03-10', 'size': 1163259, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2023-08-14T12:01', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 244}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-04-29', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-09', 'completionDateStruct': {'date': '2022-08-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-09-27', 'studyFirstSubmitDate': '2018-12-18', 'resultsFirstSubmitDate': '2023-08-14', 'studyFirstSubmitQcDate': '2018-12-18', 'lastUpdatePostDateStruct': {'date': '2023-10-23', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2023-09-27', 'studyFirstPostDateStruct': {'date': '2018-12-19', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2023-10-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-08-17', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With Adverse Events', 'timeFrame': 'From first dose of study drug until 30 days following last dose of study drug (up to 480 days)', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.'}, {'measure': 'Number of Participants With Adverse Events of Special Interest', 'timeFrame': 'From first dose of study drug until 30 days following last dose of study drug (up to 480 days)', 'description': 'Treatment emergent adverse events of special interest are defined as any adverse event of infusion site infections, infusion site reactions, hallucinations/psychosis, falls and associated injuries, polyneuropathy (peripheral neuropathy), weight loss, or somnolence from the first dose of study drug until 30 days following last dose of study drug.'}, {'measure': 'Number of Participants With Numeric Grade Equal to or Higher Than 5 and With Letter Grade Equal to or Higher Than D on the Infusion Site Evaluation Scale', 'timeFrame': 'Day 1, Day 2, Week 1, Week 2, Week 3, Week 4, Week 6, Week 13, Week 26, Week 39, and Week 52', 'description': 'Skin tolerability was assessed using the Infusion Site Evaluation Scale, a 2-part numeric (0-7) and letter (A-G) grade scale, where a notable skin reaction is defined as a reaction with a numeric grade of 6 or 7 or a letter grade of D, E, F, or G. Any observation of infusion site reaction with irritation criteria \\> 2 or \\> C was recorded as an adverse event (AE).'}, {'measure': 'Hematocrit (Hematology): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Hemoglobin (Hematology): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Red Blood Cell (RBC) Count (Hematology): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'White Blood Cell (WBC) Count (Hematology): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Neutrophils (Hematology): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Lymphocytes (Hematology): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Monocytes (Hematology): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Absolute Platelet Count (Hematology): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Mean Corpuscular Hemoglobin (Hematology): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Mean Corpuscular Volume Concentration (MCHC) (Hematology): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Prothrombin Time (PT) (Hematology): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Activated Partial Thromboplastin Time (Hematology): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Blood Urea Nitrogen (BUN) (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Creatinine (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Creatine Phosphokinase (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Total Bilirubin (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Serum Alanine Aminotransferase (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Serum Aspartate Aminotransferase (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Serum Lactate Dehydrogenase (LDH) (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Gamma-glutamyl Transferase (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Alkaline Phosphatase (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Sodium (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Potassium (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Calcium (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Inorganic Phosphorus (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Uric Acid (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Total Cholesterol (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Albumin (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Glucose (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Sodium Bicarbonate/CO2 (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Magnesium (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Creatinine Clearance (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Homocysteine (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Vitamin B6 (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Vitamin B12 (Clinical Chemistry): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'pH (Urinalysis): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Specific Gravity (Urinalysis): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 26, 39, and 52', 'description': 'Samples for clinical laboratory tests were collected at study visits, and a certified central laboratory was used to process the samples and provide results.'}, {'measure': 'Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)', 'description': 'Orthostatic blood pressure was measured after the participant had been supine (lying down with their face up) for at least 5 minutes and then, after the participant had been standing for 2 minutes. When vital sign measurements were scheduled at the same time as a blood collection, vital sign measurements were obtained prior to blood collection.'}, {'measure': 'Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)', 'description': 'Orthostatic blood pressure was measured after the participant had been supine (lying down with their face up) for at least 5 minutes and then, after the participant had been standing for 2 minutes. When vital sign measurements were scheduled at the same time as a blood collection, vital sign measurements were obtained prior to blood collection.'}, {'measure': 'Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)', 'description': 'Orthostatic pulse rate was measured after the participant had been supine (lying down with their face up) for at least 5 minutes and then, after the participant had been standing for 2 minutes. When vital sign measurements were scheduled at the same time as a blood collection, vital sign measurements were obtained prior to blood collection.'}, {'measure': 'Electrocardiogram (ECG) Mean Heart Rate: Change From Baseline to End of Study', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.'}, {'measure': 'Electrocardiogram (ECG) Aggregate PR Interval: Change From Baseline to End of Study', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.'}, {'measure': 'Electrocardiogram (ECG) Aggregate QRS Duration: Change From Baseline to End of Study', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.'}, {'measure': 'Electrocardiogram (ECG) Aggregate QT Interval: Change From Baseline to End of Study', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.'}, {'measure': 'Electrocardiogram (ECG) Aggregate QTcB Interval: Change From Baseline to End of Study', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.'}, {'measure': 'Electrocardiogram (ECG) Aggregate QTcF Interval: Change From Baseline to End of Study', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.'}, {'measure': 'Electrocardiogram (ECG) Aggregate RR Interval: Change From Baseline to End of Study', 'timeFrame': 'Baseline, Day 1 (postdose), Weeks 6 and 52', 'description': '12-lead electrocardiograms (ECGs) were recorded at study visits after the participant had been supine for at least 5 minutes. Participants were instructed to remain stationary (no talking, laughing, deep breathing, sleeping, or swallowing) for approximately 10 seconds during the ECG recording. When an ECG was recorded at a time near that of a blood collection, the ECG was obtained prior to the blood collection. ECGs on Day 1 were recorded after initiation of the continuous subcutaneous infusion (CSCI) of ABBV-951 prior to the end of the study visit.'}], 'secondaryOutcomes': [{'measure': 'Average Daily Normalized "Off" Time: Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 1, 6, 13, 26, 39, and 52', 'description': 'Upon awakening and every 30 minutes during their normal waking time, participants recorded their state in the Parkinson\'s Disease Diary (PD Diary) for 2 consecutive days prior to study visits.\n\n"Off" time is defined as periods of poor mobility, tremor, slowness, and stiffness. The daily "On" and "Off" times were normalized to a typical waking day (16 hours) to account for different sleep patterns across participants. When "Off" was the first morning symptom upon awakening, this was considered morning akinesia in this study.\n\nBaseline value is defined as the average of normalized "Off" time collected over the 2 PD Diary days before the Enrollment visit. Negative changes from Baseline indicate improvement.'}, {'measure': 'Average Daily Normalized "On" Time With Troublesome Dyskinesia: Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 1, 6, 13, 26, 39, and 52', 'description': 'Upon awakening and every 30 minutes during their normal waking time, participants recorded their state in the Parkinson\'s Disease Diary (PD Diary) for 2 consecutive days prior to study visits.\n\n"On" time is defined as periods of good motor symptom control. The daily "On" and "Off" times were normalized to a typical waking day (16 hours) to account for different sleep patterns across participants.\n\nBaseline value is defined as the average of normalized "On" time with troublesome dyskinesia collected over the 2 PD Diary days before the Enrollment visit. Negative changes from Baseline indicate improvement.'}, {'measure': 'Average Daily Normalized "On" Time Without Troublesome Dyskinesia: Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 1, 6, 13, 26, 39, and 52', 'description': 'Upon awakening and every 30 minutes during their normal waking time, participants recorded their state in the Parkinson\'s Disease Diary (PD Diary) for 2 consecutive days prior to study visits.\n\n"On" time is defined as periods of good motor symptom control. The daily "On" and "Off" times were normalized to a typical waking day (16 hours) to account for different sleep patterns across participants.\n\nBaseline value is defined as the average of normalized "On" time without troublesome dyskinesia collected over the 2 PD Diary days before the Enrollment visit. Positive changes from Baseline indicate improvement.'}, {'measure': "Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I Score: Change From Baseline to End of Study", 'timeFrame': 'Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 13, 26, 39, and 52', 'description': "The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part I assesses the participant's non-motor aspects of experiences of daily living (nM-EDL) with 13 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part I scores range from 0 to 52, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement."}, {'measure': "Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score: Change From Baseline to End of Study", 'timeFrame': 'Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 13, 26, 39, and 52', 'description': "The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part II assesses the participant's motor experiences of daily living (M-EDL) with 13 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part II scores range from 0 to 52, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement."}, {'measure': "Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score: Change From Baseline to End of Study", 'timeFrame': 'Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 13, 26, 39, and 52', 'description': "The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part III assesses the participant's motor examination (including Hoehn and Yahr stage) with 33 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part III scores range from 0 to 132, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement."}, {'measure': "Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV Score: Change From Baseline to End of Study", 'timeFrame': 'Baseline, Day 2, Weeks 1, 2, 3, 4, 6, 13, 26, 39, and 52', 'description': "The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part IV assesses the participant's motor complications with 6 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part IV scores range from 0 to 24, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement."}, {'measure': "Sleep Symptoms as Assessed by the Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score: Change From Baseline to End of Study", 'timeFrame': 'Baseline, Weeks 6, 13, 26, 39, and 52', 'description': "The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \\[never\\] to 4 \\[very often\\] with the exception of Question 1 score ranging from 0 \\[very often\\] to 4 \\[never\\]). Scores are calculated for each of the 3 domains as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Higher scores indicate higher frequency and more severe impact of PD on sleep. Negative changes indicate improvement from Baseline."}, {'measure': "Quality of Life Assessed by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index Score: Change From Baseline to End of Study", 'timeFrame': 'Baseline, Weeks 6, 13, 26, 39, and 52', 'description': "The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable). Higher scores are consistently associated with more severe symptoms of the disease such as tremors and stiffness. The results can be presented in either domain scores or as a summary index score. The full range of the PDQ-39 summary index score is from 0 (no patient-related symptoms/quality of life unaffected) to 100 (highest patient-related symptoms/low quality of life). Negative changes indicate improvement from Baseline."}, {'measure': 'The EuroQol 5-Dimension Questionnaire (EQ-5D-5L) Quality of Life Summary Index: Change From Baseline to End of Study', 'timeFrame': 'Baseline, Weeks 6, 13, 26, 39, and 52', 'description': "The EuroQol 5-dimension questionnaire (EQ-5D-5L) is a standardized non-disease specific instrument for describing and valuing health-related quality of life. The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. The health status is converted to an index value using the country-specific weighted scoring algorithm for the United States (US). The summary index value for the US ranges from a worst score of -0.109 to a best score of 1. An increase in the EQ-5D-5L total score indicates improvement."}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ["Parkinson's Disease (PD)", 'ABBV-951', 'Levodopa/Carbidopa'], 'conditions': ["Parkinson's Disease (PD)"]}, 'referencesModule': {'references': [{'pmid': '41045349', 'type': 'DERIVED', 'citation': "Pahwa R, Aldred J, Soileau MJ, Standaert DG, Fung VSC, Kimber T, Malaty IA, Santos-Garcia D, Carroll C, Henriksen T, Parab A, Yan CH, Facheris MF, Spiegel A, Harmer L, Zamudio J, Chaudhuri KR. Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials. Neurol Ther. 2025 Dec;14(6):2491-2506. doi: 10.1007/s40120-025-00827-6. Epub 2025 Oct 4."}, {'pmid': '38465885', 'type': 'DERIVED', 'citation': 'Chaudhuri KR, Facheris MF, Bergmans B, Bergquist F, Criswell SR, Jia J, Kukreja P, Mukai Y, Spiegel AM, Gupta R, Bergmann L, Pahwa R. Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa. Mov Disord Clin Pract. 2024 Jul;11(7):861-866. doi: 10.1002/mdc3.14018. Epub 2024 Mar 11.'}, {'pmid': '37632656', 'type': 'DERIVED', 'citation': "Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26."}]}, 'descriptionModule': {'briefSummary': "The purpose of this study was to assess the safety and tolerability of ABBV-951 (Foslevodopa/Foscarbidopa) in participants with Parkinson's disease (PD).\n\nThis was a single-arm study with preplanned analyses conducted by dose subgroup (Low Dose or High Dose) based on the modal total daily dose (most frequent dose) over the treatment period."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '30 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Participants with diagnosis of idiopathic Parkinson\'s Disease (PD) that is levodopa-responsive\n* Participants must be judged by the investigator to be inadequately controlled by current therapy, have recognizable/identifiable "Off" and "On" states (motor fluctuations), and have a minimum of 2.5 hours of "Off" time per day\n\nExclusion Criteria:\n\n* Participant is cognitively impaired and is not able to safely and effectively manage the drug delivery system and the diaries and is not able to adhere to the study\n* Participant is considered by the investigator to be an unsuitable candidate to receive ABBV-951 for any reason'}, 'identificationModule': {'nctId': 'NCT03781167', 'briefTitle': "A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)", 'organization': {'class': 'INDUSTRY', 'fullName': 'AbbVie'}, 'officialTitle': "A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease", 'orgStudyIdInfo': {'id': 'M15-741'}, 'secondaryIdInfos': [{'id': '2018-002144-85', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'ABBV-951 Low Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \\< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.', 'interventionNames': ['Drug: ABBV-951']}, {'type': 'EXPERIMENTAL', 'label': 'ABBV-951 High Dose Subgroup', 'description': 'After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.', 'interventionNames': ['Drug: ABBV-951']}], 'interventions': [{'name': 'ABBV-951', 'type': 'DRUG', 'otherNames': ['Foslevodopa/Foscarbidopa'], 'description': 'Solution for continuous subcutaneous infusion (CSCI)', 'armGroupLabels': ['ABBV-951 High Dose Subgroup', 'ABBV-951 Low Dose Subgroup']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35233', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'University of Alabama at Birmingham - Main /ID# 207996', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '85351', 'city': 'Sun City', 'state': 'Arizona', 'country': 'United States', 'facility': 'Banner Sun Health Res Inst /ID# 208811', 'geoPoint': {'lat': 33.59754, 'lon': -112.27182}}, {'zip': '92708', 'city': 'Fountain Valley', 'state': 'California', 'country': 'United States', 'facility': "The Parkinson's & Movement Disorder Institute - Fountain Valley /ID# 216126", 'geoPoint': {'lat': 33.70918, 'lon': -117.95367}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'country': 'United States', 'facility': 'University of Colorado Hospital /ID# 207968', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '33486', 'city': 'Boca Raton', 'state': 'Florida', 'country': 'United States', 'facility': "Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 207677", 'geoPoint': {'lat': 26.35869, 'lon': -80.0831}}, {'zip': '60611-2927', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Northwestern University Feinberg School of Medicine /ID# 208812', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '46202', 'city': 'Indianapolis', 'state': 'Indiana', 'country': 'United States', 'facility': 'Indiana Clinical Research Cent /ID# 207952', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '66160', 'city': 'Kansas City', 'state': 'Kansas', 'country': 'United States', 'facility': 'Univ Kansas Med Ctr /ID# 208963', 'geoPoint': {'lat': 39.11417, 'lon': -94.62746}}, {'zip': '40536', 'city': 'Lexington', 'state': 'Kentucky', 'country': 'United States', 'facility': 'University of Kentucky Chandler Medical Center /ID# 207603', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Massachusetts General Hospital /ID# 207993', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '55130-2400', 'city': 'Saint Paul', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Health Partners /ID# 207950', 'geoPoint': {'lat': 44.94441, 'lon': -93.09327}}, {'zip': '65203', 'city': 'Columbia', 'state': 'Missouri', 'country': 'United States', 'facility': 'University of Missouri /ID# 209043', 'geoPoint': {'lat': 38.95171, 'lon': -92.33407}}, {'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Washington University-School of Medicine /ID# 207525', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '03756', 'city': 'Lebanon', 'state': 'New Hampshire', 'country': 'United States', 'facility': 'Dartmouth-Hitchcock Medical Center /ID# 207972', 'geoPoint': {'lat': 43.64229, 'lon': -72.25176}}, {'zip': '27612', 'city': 'Raleigh', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Wake Radiology UNC REX Healthcare - Raleigh Office /ID# 209784', 'geoPoint': {'lat': 35.7721, 'lon': -78.63861}}, {'zip': '97232-2003', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Legacy Medical Group - Neurology /ID# 208031', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '29605-4255', 'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Prisma Health Cancer Institute-Faris Road /ID# 207650', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '75243-1188', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Neurology Consultants of Dallas - LBJ Fwy /ID# 207619', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77030-4202', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Baylor College of Medicine /ID# 207620', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78681', 'city': 'Round Rock', 'state': 'Texas', 'country': 'United States', 'facility': 'Central Texas Neurology Consul /ID# 216918', 'geoPoint': {'lat': 30.50826, 'lon': -97.6789}}, {'zip': '78229-3901', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Univ Texas HSC San Antonio /ID# 208958', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '98034-3029', 'city': 'Kirkland', 'state': 'Washington', 'country': 'United States', 'facility': "Booth Gardner Parkinson's Care Center /ID# 208026", 'geoPoint': {'lat': 47.68149, 'lon': -122.20874}}, {'zip': '99202-1342', 'city': 'Spokane', 'state': 'Washington', 'country': 'United States', 'facility': 'Inland Northwest Research /ID# 208122', 'geoPoint': {'lat': 47.65966, 'lon': -117.42908}}, {'zip': '53226-3522', 'city': 'Milwaukee', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'Medical College of Wisconsin /ID# 207999', 'geoPoint': {'lat': 43.0389, 'lon': -87.90647}}, {'zip': '2139', 'city': 'Concord', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Concord Repatriation General Hospital /ID# 207628', 'geoPoint': {'lat': -33.84722, 'lon': 151.10381}}, {'zip': '2145', 'city': 'Westmead', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Westmead Hospital /ID# 207633', 'geoPoint': {'lat': -33.80383, 'lon': 150.98768}}, {'zip': '5000', 'city': 'Adelaide', 'state': 'South Australia', 'country': 'Australia', 'facility': 'Royal Adelaide Hospital /ID# 207634', 'geoPoint': {'lat': -34.92866, 'lon': 138.59863}}, {'zip': '3004', 'city': 'Melbourne', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Alfred Health /ID# 207632', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'zip': '6009', 'city': 'Nedlands', 'state': 'Western Australia', 'country': 'Australia', 'facility': 'Perron Institute /ID# 207627', 'geoPoint': {'lat': -31.98184, 'lon': 115.8073}}, {'zip': '3000', 'city': 'Leuven', 'state': 'Vlaams-Brabant', 'country': 'Belgium', 'facility': 'Universitair Ziekenhuis Leuven /ID# 209058', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': '8000', 'city': 'Bruges', 'country': 'Belgium', 'facility': 'AZ Sint-Jan Brugge /ID# 208178', 'geoPoint': {'lat': 51.20892, 'lon': 3.22424}}, {'zip': '4000', 'city': 'Liège', 'country': 'Belgium', 'facility': 'Groupe Sante CHC - Clinique du MontLegia /ID# 208177', 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'zip': 'T2N 4N1', 'city': 'Calgary', 'state': 'Alberta', 'country': 'Canada', 'facility': 'University of Calgary - Movement Disorders Clinic /ID# 207342', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'zip': 'G1W 4R4', 'city': 'Québec', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Centre de Recherche St-Louis /ID# 207344', 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}}, {'zip': '2400', 'city': 'Copenhagen NV', 'state': 'Capital Region', 'country': 'Denmark', 'facility': 'Bispebjerg and Frederiksberg Hospital /ID# 207669'}, {'zip': '8200', 'city': 'Aarhus N', 'state': 'Central Jutland', 'country': 'Denmark', 'facility': 'Aarhus University Hospital /ID# 207668', 'geoPoint': {'lat': 56.20367, 'lon': 10.17317}}, {'zip': '5000', 'city': 'Odense C', 'state': 'Region Syddanmark', 'country': 'Denmark', 'facility': 'Odense University Hospital /ID# 207871', 'geoPoint': {'lat': 55.40841, 'lon': 10.39538}}, {'zip': '89081', 'city': 'Ulm', 'state': 'Baden-Wurttemberg', 'country': 'Germany', 'facility': 'Universitaetsklinikum Ulm /ID# 208602', 'geoPoint': {'lat': 48.39841, 'lon': 9.99155}}, {'zip': '14547', 'city': 'Beelitz-Heilstätten', 'country': 'Germany', 'facility': 'Kliniken Beelitz GmbH /ID# 208600', 'geoPoint': {'lat': 52.25965, 'lon': 12.92662}}, {'zip': '83527', 'city': 'Haag', 'country': 'Germany', 'facility': 'InnKlinikum Haag /ID# 208601', 'geoPoint': {'lat': 50.30379, 'lon': 12.07614}}, {'zip': '98124', 'city': 'Messina', 'country': 'Italy', 'facility': 'IRCCS Centro Neurolesi Bonino Pulejo /ID# 207975', 'geoPoint': {'lat': 38.19394, 'lon': 15.55256}}, {'zip': '20133', 'city': 'Milan', 'country': 'Italy', 'facility': 'Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 207955', 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}, {'zip': '35128', 'city': 'Padua', 'country': 'Italy', 'facility': 'Azienda Ospedaliera di Padova /ID# 208077', 'geoPoint': {'lat': 45.40797, 'lon': 11.88586}}, {'zip': '070-8644', 'city': 'Asahikawa-shi', 'state': 'Hokkaido', 'country': 'Japan', 'facility': 'National Hospital Organization Asahikawa Medical Center /ID# 210914'}, {'zip': '616-8255', 'city': 'Kyoto', 'state': 'Kyoto', 'country': 'Japan', 'facility': 'National Hospital Organization Utano National Hospital /ID# 210912', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'zip': '565-0871', 'city': 'Suita-shi', 'state': 'Osaka', 'country': 'Japan', 'facility': 'Osaka University Hospital /ID# 210913'}, {'zip': '113-8431', 'city': 'Bunkyo-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Juntendo University Hospital /ID# 210915'}, {'zip': '187-8551', 'city': 'Kodaira-shi', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'National Center of Neurology and Psychiatry /ID# 210911'}, {'zip': '3015 GD', 'city': 'Rotterdam', 'state': 'South Holland', 'country': 'Netherlands', 'facility': 'Erasmus Medisch Centrum /ID# 208168', 'geoPoint': {'lat': 51.9225, 'lon': 4.47917}}, {'zip': '3435 CM', 'city': 'Nieuwegein', 'country': 'Netherlands', 'facility': 'St. Antonius Ziekenhuis /ID# 208529', 'geoPoint': {'lat': 52.02917, 'lon': 5.08056}}, {'zip': '197101', 'city': 'Saint Petersburg', 'state': 'Sankt-Peterburg', 'country': 'Russia', 'facility': 'Academician I.P. Pavlov First St. Petersburg State Medical University /ID# 216303', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '197706', 'city': 'Sestroretsk', 'state': 'Sankt-Peterburg', 'country': 'Russia', 'facility': 'City Clinical Hospital #40 /ID# 216301', 'geoPoint': {'lat': 60.09801, 'lon': 29.96378}}, {'zip': '03203', 'city': 'Elche', 'state': 'Alicante', 'country': 'Spain', 'facility': 'Hospital General Universitario de Elche /ID# 209777', 'geoPoint': {'lat': 38.26218, 'lon': -0.70107}}, {'zip': '08907', 'city': "L'Hospitalet de Llobregat", 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Universitario de Bellvitge /ID# 209539', 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}, {'zip': '15006', 'city': 'A Coruña', 'country': 'Spain', 'facility': 'Hospital Universitario A Coruna - CHUAC /ID# 212147', 'geoPoint': {'lat': 43.37135, 'lon': -8.396}}, {'zip': '08041', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Santa Creu i Sant Pau /ID# 208240', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '18014', 'city': 'Granada', 'country': 'Spain', 'facility': 'Hospital Universitario Virgen de las Nieves /ID# 208242', 'geoPoint': {'lat': 37.18817, 'lon': -3.60667}}, {'zip': '28034', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario Ramon y Cajal /ID# 208241', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '41013', 'city': 'Seville', 'country': 'Spain', 'facility': 'Hospital Universitario Virgen del Rocio /ID# 208239', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': 'SE 221 41', 'city': 'Lund', 'state': 'Skåne County', 'country': 'Sweden', 'facility': 'Skane University Hospital Lund /ID# 207811', 'geoPoint': {'lat': 55.70584, 'lon': 13.19321}}, {'zip': '113 65', 'city': 'Stockholm', 'state': 'Stockholm County', 'country': 'Sweden', 'facility': 'Centrum for neurologi /ID# 207716', 'geoPoint': {'lat': 59.32938, 'lon': 18.06871}}, {'zip': '413 46', 'city': 'Gothenburg', 'state': 'Västra Götaland County', 'country': 'Sweden', 'facility': 'Sahlgrenska University Hospital /ID# 207718', 'geoPoint': {'lat': 57.70716, 'lon': 11.96679}}, {'zip': 'DD2 1UB', 'city': 'Dundee', 'state': 'Scotland', 'country': 'United Kingdom', 'facility': 'NHS Tayside /ID# 209242', 'geoPoint': {'lat': 56.46913, 'lon': -2.97489}}, {'zip': 'SE5 9RS', 'city': 'London', 'country': 'United Kingdom', 'facility': "King's College Hospital NHS Foundation Trust /ID# 208413", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'PL6 5FP', 'city': 'Plymouth', 'country': 'United Kingdom', 'facility': 'University Hospital Plymouth NHS Trust /ID# 208447', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}], 'overallOfficials': [{'name': 'ABBVIE INC.', 'role': 'STUDY_DIRECTOR', 'affiliation': 'AbbVie'}]}, 'ipdSharingStatementModule': {'url': 'https://vivli.org/ourmember/abbvie/', 'timeFrame': 'For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/', 'ipdSharing': 'YES', 'description': 'AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.', 'accessCriteria': 'Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AbbVie', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}